Supplementary Materials for

Distinct genetic liability profiles define clinically relevant patient strata across common diseases

Lucia Trastulla^{1,2,3}, Sylvain Moser^{1,2,4}, Laura T. Jiménez-Barrón^{1,4}, Till F.M. Andlauer¹, Moritz von Scheidt^{5,6}, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Monika Budde⁷, Urs Heilbronner⁷, Sergi Papiol⁷, Alexander Teumer^{9,10,11}, Georg Homuth¹², Peter Falkai¹³, Henry Völzke^{9,10}, Marcus Dörr^{8,9}, Thomas G. Schulze⁷, Julien Gagneur¹⁴, Francesco Iorio³, Bertram Müller-Myhsok^{1,15}, Heribert Schunkert^{5,6} & Michael J. Ziller^{1,16,17*}

*Correspondence to: ziller@uni-muenster.de

This PDF file includes:

Supplementary Fig. 1 to 28 Supplementary Tables 1 to 7 Captions for Supplementary Data 1 to 7

Other Supplementary Materials for this manuscript include the following:

Supplementary Data 1 to 7

Prior features construction in tissue-specific models Significant genes associated with Coronary Artery Disease Significant pathways associated with Coronary Artery Disease Group-specific Pathways for CAD cases clustering in Liver Significant genes associated with Schizophrenia Significant pathways associated with Schizophrenia Group-specific Pathways for SCZ cases clustering in Dorsolateral prefrontal

cortex



Supplementary Fig. 1. Workflow CASTom-iGEx pipeline.

CASTom-iGEx is composed of 3 modules: 1) Prior Learned elastic-net regression (PriLer) to train gene expression prediction models on reference panels integrating SNPs prior information, 2) application to genotype-only datasets, conversion to gene levels T-score and pathway levels scores and identification of differentially active genes and pathways between affected and unaffected individuals, 3) patient stratification based on gene levels T-score to characterize biological pathways and endophenotypic differences.



Supplementary Fig. 2. PriLer steps to model gene expression integrating prior variant knowledge.

The first step considers only heritable genes and builds an elastic-net regression model for each gene in a nested cross validation setting without prior information. The second step uses the optimal gene specific α - λ parameters combination found in step 1 to build a PriLer model in the same nested cross-validation frame in order to find the optimal E parameter that controls the magnitude of the prior weights. Step 1 and 2 are also used to evaluate the prediction models based on R^2_{cv} . The third step finds the optimal α - λ parameter on the entire set (single cross validation) from elastic-net regression and uses these α - λ pairs together with optimal E parameter from step 2 to build PriLer models on the entire dataset. The fourth step considers only genes not heritable, repeats step 3 but instead of deriving prior coefficients, it uses the ones computed from heritable genes. Finally, in order to evaluate the models based on R^2_{cv} for genes not heritable, step 1 and 2 are also repeated with CV-specific prior coefficients derived in step 2.



Supplementary Fig. 3. Comparison PriLer and elastic-net regression imputation models.

For each tissue in GTEx/CMC panels comparison of PriLer and elastic-net regression without prior regarding **a.** number of reliable genes i.e. $R^2_{cv} > 0$ and $R^2 > 0.01$, **b.** number and percentage of genes among the reliable ones in PriLer models having better prediction performance (R^2_{cv}) in PriLer compared to elastic-net, **c.** number of regulatory variants i.e. variant that regulates at least 1 gene, **d.** fraction of regulatory variants that intersect with at least 1 prior feature used in PriLer tissue models, **e.** Regulatory variants robustness in whole blood measured via bootstrapping 100 individuals 10 times and computing Jaccard index in each pair of repetition for PriLer and elastic-net models (p-value from Wilcoxon-Mann-Whitney test). Boxplot elements include median as central line, 1st and 3rd quartiles as box limits, 1.5 interquartile ranges from 1st and 3rd quartiles as corresponding whiskers.





a. Number of total genes across the heritable and not heritable categories. **b.** Number of reliable genes across the heritable and not heritable categories. **c.** Average R² on test folds for reliable genes across all tissues, divided by heritable (yellow) and not heritable (grey) genes. The tissues are ordered on the y-axis according to their sample size. Boxplot elements include median as central line, 1st and 3rd quartiles as box limits, 1.5 interquartile ranges from 1st and 3rd quartiles as corresponding whiskers.



Supplementary Fig. 5. Simulation of prior features to test weights their relevance in Artery

Coronary tissue.

In the first scenario (Random Variants), 2 prior features were randomly generated 50 times heart left ventricle Var random and heart left ventricle Var random2x using the same size/ twice the number of prior features as in heart left ventricle (pink). In the second scenario (Random GREs), open chromatin regions were randomly selected (i.e. gene regulatory elements GREs) from ChIP-Seq H3k27ac data 50 times using the same or twice feature set size as heart left ventricle and intersected the latter with variants location to create heart left ventricle Epi random and heart left ventricle Epi random2x priors (pink). This included also a prior feature related to brain tissue Ctrl 150 allPeaks cellRanger (blue) as well as random prior heart left ventricle Epi random noint sampling among GREs excluding the ones in the baseline prior features and in the same size as GREs for heart left ventricle. In both scenarios, we created PriLer models including other 6 fixed prior features for Artery Coronary. a, e. mean \pm SD prior weights for each prior feature, **b**, **f**. mean percentage of variants in the random priors features that are in common with fixed features used in the model, c., g. mean \pm SD number of variants associated to each prior features, d., h. mean \pm SD update of prior weights at each iterative step.



Supplementary Fig. 6. Comparison PriLer with TWAS and prediXcan imputation models.

Comparison of PriLer to prediXcan and TWAS build on GTEx v6p 33 (tissues) and CMC datasets. Number and percentage of genes with better performance (R^2_{cv}) and higher number of regulatory variants in **a**. PriLer compared to TWAS and in **b**. PriLer compared to prediXcan. **c**. Fraction of regulatory variants intersecting tissue specific prior information used in PriLer model across the three methods. **d**. External validation of regulatory variants enrichment for PriLer in biologically meaningful regions using DNase I hypersensitive sites (DHSs): cumulative distribution of regulatory variants overlapping with a certain number of DHS biosamples, differences in distributions between PriLer and elasic-net, TWAS or prediXcan tested with Kolmogorov-Smirnoff test.



Supplementary Fig. 7. TWAS summary results for CAD.

a. Number of FDR 0.05 significant genes per number of tissues in which they are detected for each CAD related tissue **b.** number of detected reliable genes compared to the number of significant genes, **c.** fraction of significant genes uniquely detected in a tissue compared to number of significant genes. **d.** Lower-triangular (green): percentage of imputed genes that are in common between 2 tissues (Jaccard index), upper-triangular (orange): Spearman correlation of CAD Z-statistics among shared genes.



Supplementary Fig. 8: P-value calibration for TWAS and PALAS in whole blood

Distribution of p-values for two analyses (TWAS and PALAS) for random phenotypes in whole blood across 50 simulations, using size matched cases/control and the age/sex distributions. **a-c.** Count of p-values in specific intervals for gene T-scores, Reactome pathway-scores, and GO pathway-scores, respectively. **d-f.** Expected and observed p-value distributions for CAD (represented by dots) and random phenotypes (represented by triangles) for gene T-scores, Reactome pathway-scores, and GO pathway-scores. The diagonal line represents the expected distribution and the green shaded area shows the 95% confidence interval from a beta distribution. Blue points indicate genes that are significant at a 0.05 false discovery rate level, corrected separately for CAD and each simulation.



Supplementary Fig. 9. PALAS summary results for CAD.

С

a. Significant pathways linked to CAD in each tissue with tissue-specific FDR of less than or equal to 0.05. The bars represent the number of pathways and their color represents the number of genes that are reliably predicted in that tissue (based on T-score genes). b. Venn-diagram of PALAS significant pathways (FDR 0.05), pathways significant from hyper-geometric test (FDR 0.05) using TWAS significant genes and pathways significant from MAGMA (FDR 0.05) applied to GWAS performed on matched UK Biobank data (MAGMA UKBB) or GWAS summary statistics from CAD GWAS in ²⁰. c. Pathways with at least one gene significantly associated with CAD based on TWAS and filtered based on the prioritization criteria (computed from more than 5 and less or equal than 200 T-score genes or more than 2 if pathway coverage is higher than 10%, originally including less than 200 genes and reaching at least 0.0001 as nominal significance). The left panel shows PALAS Z-statistic (x-axis) color coded by the tissue of origin and indicating the gene pathway coverage for only one exemplar (best coverage) per most significant gene (in the right panel). The right panel shows the number of disrupted pathways by a certain gene. Acronyms in parenthesis indicate the initials of the tissue considered (AS = Adipose Subcutaneous, AVO = Adipose Visceral Omentum, AG = Adrenal Gland, AA = Artery Aorta, AC = Artery Coronary, CS = Colon Sigmoid, CT = Colon Transverse, HAA = Heart Atrial Appendage, HLV = Heart Left Ventricle, L = Liver, WB = Whole Blood). d. GO peptidyl-tyrosine phosphorylation in adipose subcutaneous. The pathway significance is indicated by the dashed horizontal line, the coloured squares show genes included in that pathway and the corresponding TWAS p-value (y-axis) and the dots indicate the matched GWAS p-value of SNPs regulating those genes with colour reflecting PriLer regulatory coefficients.



Supplementary Fig. 10. Gene correlation relevance for PALAS results.

a-b. This figure shows the simulation of pathway structure using gene expression data in whole blood from the same locus with a concordant effect size sign and TWAS nominal p-value of less than 0.1. The simulation covers 46 pathways in total. **a.** Each simulated pathway is a point with a color indicating the number of genes in the pathway. The X-axis represents the average difference in Z-statistic between the pathway and the included genes, while the Y-axis shows the absolute value of the mean correlation among the genes in the pathway. **b.** Similar to a., but with the X-axis showing -log 10 p-value from PALAS. **c-d.** Improvement in pathway significance related to the

individual gene level p-values based on TWAS that are included in it as a function of the correlation between the genes (y-axis). Each point in the figure represents a pathway from GO **c**., Reactome **d**., or WikiPathways **e**., and the color code shows the number of genes that were used to calculate the pathway-score. The X-axis displays the average difference in Z-statistics between a pathway and its corresponding genes, and the Y-axis shows the mean correlation between those genes.



Supplementary Fig. 11. Down-sampling of GTEx reference panel sample in artery aorta and

heart left ventricle gene expression datasets

a. Number of reliable genes from PriLer compared to the training sample size across the two subsampled tissues at 50%, 70% and 90%. **b.** PriLer model estimates in terms of average R^2 on test folds (R²_{CV}) considering all reliable genes (left) and reliable genes in common of the tissue-specific sub-sampled models (right). The grey line connects the median distribution for the increasing model sample size. c-d. Heatmap with lower triangular part (green) indicating the percentage of shared genes/pathways computed via Jaccard similarity and the upper triangular part (orange) indicating the Spearman correlation of CAD Z-statistic for the genes/pathways in common. c. refers to TWAS results and d. to PALAS. e-h. Receiver operating characteristic (ROC) curve using significant genes/pathways (FDR 0.05) in the full sample size model (100%) as ground truth and the absolute Z-statistic as prediction values across sub-sampled percentages. For each comparison, only genes/pathways in common are considered. e. TWAS results in artery aorta, f. PALS results in artery aorta, g. TWAS results in heart left ventricle, h. PALS results in heart left ventricle. Area under the curve (AUC) is shown in each plot with color matching the sub-sampled model legend. Boxplot elements include median as central line, 1st and 3rd quartiles as box limits, 1.5 interquartile ranges from 1st and 3rd quartiles as corresponding whiskers.



Supplementary Fig. 12. Comparing clustering structure of CAD patients across tissues.

a. Proportion of individuals in each tissue-specific cluster across 19,026 patients together with modularity from Louvain clustering. **b.** Normalized mutual information (NMI) for each pair of tissue-specific clustering structure. **c.** Number significant genes and loci (tissue specific FDR \leq 0.01) associated with each group in liver clustering from Wilcoxon-Mann-Whithney (WMW) test of gr_i versus remaining patients combing all tissues. **d.** -log10(p-value) testing clustering results with PCs from 1 to 10 and Age (Kruskal-Wallis test) and with Sex and Assessment Centre (χ^2 test) before (x-axis) and after (y-axis) correction of gene T-scores for PCs. Red dashed line represents the intercept. **e.** NMI between clustering results using genes corrected for PCs or uncorrected.



Supplementary Fig. 13. Genes and covariates associated with clustering structure in liver. **a.** Age distribution for each group (p-values from Kruskal-Wallis) **b.** Sex distribution for each group (p-values from Chi-squared test). **c.** Distribution of PCs 1 to 10 for each group (p-values from Kruskal-Wallis test). **d.** X-axis shows the coefficient of variation, absolute value of WMW estimates divided by confidence interval ranges, for group-specific test. Y-axis indicates the first

5 genes per group based on WMW p-value and significant group-specific principal components (FDR ≤ 0.05). **e.** Reproducibility of group-specific loci on predicted groups in 9 external cohorts (CARDIoGRAM), the x-axis shows the number of loci across all tissues associated with each group in UKBB, the y-axis shows how many of these loci have the same sign and are significant at the nominal level of 0.05 for the strongest association of the WMW estimates in the predicted clustering structure. Boxplot elements include median as central line, 1st and 3rd quartiles as box limits, 1.5 interquartile ranges from 1st and 3rd quartiles as corresponding whiskers.



Supplementary Fig. 14. Comparison of CAD clustering structure based on T-scores in liver and based on Principal Components from genotype data in UKBB.

CAD cases are clustered using the first 40 PCs from UKBB (standardized). a. UMAP based on PCs, where the color refers to the assigned PC clustering. b. The comparison between PC clustering and gene T-score grouping is shown in terms of -log10 p-value of a chi-squared test (left panel) and NMI (right panel). The dashed line refers to the nominal p-value of 0.05, and the comparison is shown for each tissue. c. The histogram of NMI between the cluster from PCs and 10,000 randomly assigned groups with the same size as liver clustering is shown. The dashed line refers to the NMI comparing PCs and the actual liver clustering. d. The results of pairwise Fisher's Exact tests between a group detected in the PC clustering (columns) and a group detected in liver clustering (rows) are presented in a heatmap that indicates the computed odds ratio. Nonsignificant results at the nominal level of 0.01 are highlighted with an "x". e. Investigation of enrichment in the assessment center for groups 1 in liver and 7 in PC clustering. The x-axis indicates the fraction of (observed - expected)/expected counts as computed from the chi-squared statistic across the centers versus a group assignment (gr i or not gr i), while the y-axis indicates the center assignment. f. The results of testing each endophenotype are presented in dots that indicate the -log10 p-value of the most significant group-specific difference in PCs (x-axis) and liver (y-axis) clustering. The dashed lines refer to p-value = 0.001, and the color reflects the FDR significance threshold. g. Forest plot of the group-specific differences for the three endophenotypes that are significant in both PCs and liver clustering. The x-axis shows the regression coefficient from a GLM test of gr i vs all remaining samples with 95% CI. The dots that are not shaded indicate the groups with the most significant association in terms of p-value.





CELSR2 (L) AC007246.3 (AS) NBEAL1 (AA) SOWAHB (AC) RP1-167G20.1 (HLV) 5 HLA-B (HAA) 0 PRSS51 (AG) -5 TAS2R15 (AVO) RP11-362K2.2 (AS) ADAM1B (HAA) EMC9 (AG) 0 HERC2 (WB) RP11-507J18.2 (AC) TRIM47 (WB) SLC52A3 (AS)







Supplementary Fig. 15. Genes and pathways associated with CAD liver clustering structure

a. Wilcoxon-Mann-Whithney (WMW) estimates for the most group-specific significant gene in the 16 group associated loci. In parenthesis the tissue considered with acronyms indicating to the tissue name initials. Row annotation on the left indicate the corresponding CAD Z-statistics from TWAS. **b.** WMW estimates (capped) for 271 significant pathways, considering only the most significant tissue per pathway. The rows are labeled with the names of the significant pathways, with the tissue considered indicated in parentheses. The left-side annotations show the corresponding CAD Z-statistics from PALAS.



Supplementary Fig. 16 Genes/pathways and endophenotype associations with random clustering structure

Random clustering of CAD patients maintaining the same group size as liver grouping. a. X-axis NMI (x-axis) and -log10 p-values (y-axis) from χ^2 statistics between liver clustering and random groupings. b. Quantile-quantile representation of the association between gene T-scores and group-wise specific (gri vs all remaining) testing, using the WMW method across all tissues. The expected p-values follow a uniform distribution, and the plot shows a dashed line along the diagonal, with a shaded green area representing a 95% confidence interval from the beta distribution. Each line in the plot corresponds to one of the 10 simulations. c. Number of significant associations that passed the FDR threshold for each of the 10 random clustering experiments as a function of varying FDR levels on the x-axis. d. Similar to b., pathway-scores group-specific differences for the selected gene-sets (Jaccard similarity ≤ 0.2). e. Similar to c., pathway-scores group-specific counts based on FDR thresholds. f. Volcano plot of cluster-specific endophenotype differences. The x-axis represents the β regression coefficient from the GLM, which refers to the features of gr i versus the remaining cases, while the y-axis shows the corresponding -log10 pvalue. Each grey dot represents an endophenotype among the 637 UK Biobank phenotypes that was tested for a random clustering configuration out of 50 repetitions. In contrast, each black dot refers to the endophenotype testing on the actual liver clustering. In both cases, the size of the dots corresponds to the significance of the test after correction (FDR ≤ 0.05).



Figure S17

Supplementary Fig. 17. Replication of CAD clustering on SHIP-Trend cohort

Prediction of liver clustering structure on SHIP-Trend cohort. **a.** Y-axis indicates the fraction of CAD patients assigned to each group in UKBB data set and on the projected clustering for SHIP-Trend individuals. **b.** In whole blood, correlation of beta regression coefficients of group-wise

gene level differences derived from predicted gene expression values (x-axis) and measured gene expression values in SHIP cohort (y-axis), considering only cluster-specific genes form imputed values in SHIP samples (WMW FDR 0.05 threshold). c. Similar to (B) but considering pathwaylevel group-specific differences and including only pathways with WMW nominal p-value below of 0.05, when testing imputed pathway values. d. Including only cluster-specific genes from the UKBB cohort, comparison between imputed gene expression (x-axis) and measured gene expression differences (y-axis), divided per group. Measured differences are adjusted for multiplecorrection via BH procedure on this subset of genes. Each gene (dot) is colored by the significance (FDR 0.05) it reaches for both tests in SHIP cohort: grey not significant in both tests, purple significant in both and orange significant only when testing imputed gene expression differences. e. Volcano plots showing group-specific differences across all measured genes in whole blood for SHIP cohort. Dots in blue indicate genes passing FDR 0.05 threshold. f. Forest plot of clusterspecific endophenotype results in SHIP cohort. Out of the 20 clinical variable tested, the plot shows regression coefficient with 95% CI from GLM (x-axis) of those reaching nominal significance below 0.05. The full dots indicate results reaching FDR 0.05 threshold.



Supplementary Fig. 18 Endophenotype and treatment response analyses on CAD clustering a. Among the 212 endophenotypes measured in UKBB with at least one CAD associated and group specific pathway, forest plot shows significantly different ones (FDR ≤ 0.05) in at least one group (gr_i versus remaining patient) using Generalized Linear Model (GLM), indicating regression coefficient (β_{GLM}) with 95% Confidence Interval (CI). Full dot indicates that β_{GLM} is significant after BH correction. This panel include binary or ordinal categorical phenotypes (m-male, ffemale), continuous phenotypes are in Fig. 2e. **b.** Heatmap including PALAS Z-statistics for the

19 cluster-specific measured endophenotypes (rows) and a selection of cluster-specific pathways (columns). The * indicates associations that reach FDR 0.05 significance in PALAS. The capital abbreviation in the pathway names indicates the acronym of the tissue considered. HAA: Heart Atrial Appendage, CT: Colon Transverse, AG: Adrenal Gland, L: liver, HLV: Heart Left Ventricle, AA: Artery Aorta, AC: Artery Coronary. **c.** Treatment response showing the effect of glucosamine and cholesterol-lowering medications in each group for selected phenotypes. X-axis shows regression coefficient with 95% CI from GLM in each group, full dots indicate groups that are significantly different in a pairwise comparison after BH correction (pairwise comparison-specific and treatment-specific), tested using Z-test for comparing regression coefficients. **d.** Distribution of original CRP values in each group when taking or not glucosamine supplements, y-axis is cropped at CRP=20 mg/L excluding 330 outliers. Boxplot elements include median as central line, 1st and 3rd quartiles as box limits, 1.5 interquartile ranges from 1st and 3rd quartiles as corresponding whiskers.











replication P > 0.05 replication P < 0.05

d

Figure S19

34

Supplementary Fig. 19: PALAS summary results for SCZ and replicability.

a. Significant pathways linked to SCZ in each tissue with tissue-specific FDR of less than or equal to 0.05. The bars represent the number of pathways, and their color represents the number of genes that are reliably predicted in that tissue (based on T-score genes). b. The number of pathways that are statistically significant (FDR ≤ 0.05) categorized into three groups based on the significance of their genes. The first group includes pathways where at least one gene is more significant than the pathway (ivory). The second group includes pathways where all genes are less significant than the pathway, but at least one gene has an FDR ≤ 0.05 (green). The third group includes pathways where all genes are less significant than the pathway and do not pass the FDR 0.05 threshold (light blue). c. Pathways with at least one gene more significant and no genes in the MHC locus, filtered using the prioritization criteria (computed from more than 5 and less or equal than 200 T-score genes or more than 2 if pathway coverage is higher than 10%, originally including less than 200 genes and reaching at least 0.0001 as nominal significance). The left panel shows PALAS Zstatistic (x-axis) color coded by the tissue of origin and indicating the gene pathway coverage for only one exemplar (best coverage) per most significant gene (in the right panel). The right panel shows the number of disrupted pathways by a certain gene. Acronyms in parenthesis indicate the initials of the tissue considered. d. CMC gene-set "De Novos: SCZ loss of function" in DLPC tissue. The dots indicate -log10(p-values) from TWAS for all tested genes in the given tissue. Genes that are included in the pathway are labelled and colored. The dashed line represents the log10(p-value) of the considered pathway from PALAS. e. Incremental significance change of pathways is evaluated as genes from "De novos: SCZ LoF" are added one-by-one to the test gene set, with each addition leading to the computation of a pathway score from lowest to highest gene based on Z-statistic. The X-axis shows the number of genes in the incremental pathway analysis,

while the Y-axis shows the corresponding Z-statistic level for each configuration. The labelled dot on the plot represents the gene that was added at each step, with the colour code indicating the actual TWAS p-value of that gene. Additionally, the color of the label indicates the sign of the gene-specific Z-statistic (blue for negative and red for positive). **f.** Reproducibility of gene levels T-scores (left) and pathway scores (right) on CMC data-set (478 individuals). X-axis shows the fraction of significant genes in PGC that have the same effect sign (Z-statistic) in CMC cohort, pvalues are computed from one-sided sign test (* * ** = P \leq 0.0001). The fraction of genes concordant and nominal at a p-value threshold of 0.05 is shown in the yellow bar.


Supplementary Fig. 20. Comparison of clustering structure for SCZ patients across tissues. a. Proportion of individuals in each tissue-specific cluster among 22,687 patients for 2 different filtering strategies: genes are clumped based on imputed R^2 at Pearson correlation 0.9 (left) and correlation 0.1 (right). b. Normalized mutual information (NMI) for each pair of tissue-specific clustering structure in the 2 filtering strategies. Upper triangular matrix refers to |corr| < 0.9 preprocessing, lower triangular matrix to |corr| < 0.1 preprocessing, the diagonal shows NMI between the two filtering strategies in the same tissue.



Supplementary Fig. 21: Genes and covariates associated with SCZ clustering structure in DLPC.

a. Uniform manifold approximation and projection (UMAP) first 2 components of gene T-scores in DLPC standardized across SCZ patients, corrected for PCs, and multiplied by Z-statistic SCZ associations. Each dot represents a patient in the transformed UMAP space colored by the cluster membership. **b.** Number significant genes and loci (tissue specific FDR ≤ 0.01) associated with each group from Wilcoxon-Mann-Whithney (WMW) test of gri versus remaining patients combing all tissues. c. Distribution of PCs 1 to 10 for each group (p-values from Kruskal-Wallis test). d. Contingency table that displays the group and cohort structure, where each square in the table represents the fraction of patients in a group (rows) that belong to a particular cohort (columns). Each row of the table adds up to 1. e. X-axis shows the coefficient of variation, absolute value of WMW estimates divided by confidence interval ranges, for group-specific test. Y-axis indicates the first 5 genes per group based on WMW p-value and significant group-specific principal components (FDR ≤ 0.05) **f-g.** Prediction of cluster membership for SCZ cases in external cohort (scz boco eur) through projection, validated via f. fraction of cases for each group in model (35 PGC2 cohorts) and external ones, g. group-specific Spearman correlation of WMW estimates in model and each external cohort only from genes that are significantly associated with that group across all tissues. Boxplot elements include median as central line, 1st and 3rd quartiles as box limits, 1.5 interquartile ranges from 1st and 3rd quartiles as corresponding whiskers.



Supplementary Fig. 22: Comparison SCZ clustering structure based on DLPC and based on PCs.

SCZ cases clustered using the first 20 PGC PCs (standardized). **a.** UMAP based on PCs, where the color refers to the assigned PC clustering. **b.** For each tissue, comparison between PC clustering and gene T-score grouping is shown in terms of -log10 p-value of a chi-squared test (left panel) and NMI (right panel). **c.** The histogram of NMI between the cluster from PCs and 10,000

randomly assigned groups with the same size as liver clustering is shown. The dashed line refers to the NMI comparing PCs and the actual DLPC clustering. **d.** The results of pairwise Fisher's Exact tests between a group detected in PC clustering (columns) and a group detected in DLPC clustering (rows) are presented in a heatmap that indicates the computed odds ratio. Nonsignificant results at the nominal level of 0.01 are highlighted with an "x". **e.** The results of testing each endophenotype are presented in dots that indicate the -log10 p-value of the most significant group-specific difference in PCs (x-axis) and DLPC (y-axis) clustering. The dashed lines refer to p-value = 0.001, and the color reflects the FDR significance threshold. **f.** Forest plot of the groupspecific differences for the endophenotypes that are significant in PCs cluster at FDR 0.1 threshold. The x-axis shows the regression coefficient from a GLM test of gr_i vs all remaining samples with 95% CI. The dots that are not shaded indicate the groups with the most significant association in terms of p-value.



Supplementary Fig. 23: Pathways associated with SCZ clustering structure in DLPC.

a. The number of significant pathways (tissue specific FDR ≤ 0.01) associated with each group from the Wilcoxon-Mann-Whitney (WMW) test of group i versus the remaining patients. The pathways included in the analysis are from Reactome and GO and are filtered such that Jaccard similarity ≤ 0.2 , retaining only the pathways with the highest coverage and removing significant pathways having discordant WMW estimates across tissues. **b.** For each group, the number of significant pathways passing the WMW p-value threshold is plotted on the y-axis against the p-value threshold on the x-axis, split into pathways that include at least one gene in the major histocompatibility complex (MHC) (top panel) and those that do not (bottom panel). **c.** The WMW

testing each group against the rest (columns) and considering only the most significant tissue per pathway when repeated. The tissue tested is indicated by an acronym for the initial of the tissue name in parentheses. The row annotation on the left refers to the corresponding schizophrenia Zstatistics from the Psychiatric Genomics Consortium schizophrenia (SCZ) PGC2-PALAS dataset.



Supplementary Fig. 24. Evaluation of gene-RS performance in resembling actual endophenotypes

Validation of cluster-reliable measure (CRM) in CAD. **a.** Meta-analysis of gene-RS differences built on 9 CARDIoGRAM cohorts or **b.** UKBB. For the validation on UKBB, we included the same individuals used to build the original TWAS coefficients and to estimate R2. In both (A-B), CRM (x-axis) is compared to the actual CAD endophenotypic differences detected in each tissue-specific clustering, combined all together. On the left panel, the y-axis indicates the precision computed as the fraction of group-specific gene-RS differences having the same sign of GLM regression coefficient in the actual CAD endophenotype analysis, among all the endophenotypes passing CRM threshold. On the right panel, the y-axis indicates the number of phenotypes passing that CRM threshold.



Supplementary Fig. 25. Cognitive performance differences from gene-RS in DLPC SCZ clustering.

a. Forest-plot of generalized linear model testing group-specific differences in gene-RS for a subset of cognitive performance phenotypes with 95% CI. Each dot in the plot represents the adjusted regression coefficient, which is filled if FDR is less than or equal to 0.05. The color of the dot corresponds to the credibility of the results according to the CRM threshold, with darker grey indicating more reliable results. b. Spider plot showing group-specific means (including

controls) of gene-RS for cognitive performance phenotypes, rescaled to a range of 0-100. Each color on the chart represents a cognitive test class in the plot a.



Figure S26

Supplementary Fig. 26. Replication of PGC SCZ clustering on PsyCourse external cohort. Prediction of cluster membership for SCZ cases in external cohort (PsyCourse) through projection, validated via **a.** fraction of cases for each group in model (35 PGC2 cohorts) and external ones, **b.** group-specific Spearman correlation of WMW estimates in model and each external cohort only from genes that are significantly associated with that group across all tissues.



Supplementary Fig. 27: Pathway analysis and drug response based on up- and down-regulated group-specific pathways.

For each group in SCZ clustering **a.** and CAD clustering **b.**, the number of associated drugs from "gep2pep" output are shown (FDR ≤ 0.05 , right panel) and the corresponding enrichment score from GSEA (left panel), including only those drugs whose name matched ATC annotation. The x-axis in the left panel indicates the enrichment score (ES) and dot size indicate the -log10 p-

value of GSEA. The GSEA tests the cumulative changes of pathway response to a drug administration in a cluster-specific set of pathways (either up- or down-regulated, based on WMW estimate sign).



Supplementary Fig. 28: Trans-ancestry application of CASTom-iGEx.

CASTom-iGEx pipeline is applied in the context of CAD across Indian individuals in UKBB data set. **a.** Reproducibility of TWAS (left) and PALAS (right) significant results for UKBB white British (UKBB WB) cohort in the UKBB Indian population. X-axis shows the fraction of significant genes in UKBB WB that have the same effect sign (Z-statistic) in UKBB Indian. P- values are computed from one-sided sign test (* = $P \le 0.05$, ** = $P \le 0.01$, * * * = $P \le 0.001$, * * ** = $P \le 0.0001$). The fraction of genes concordant and nominal at a p-value threshold of 0.05 is shown in the yellow bar. **b.** Fraction of reproduced significant results based on Z-statistic sign for UKBB WB in Indian UKBB cohort (red) and CARDIoGRAM meta-analysis (green). **c.** Projection of CAD cases clustering in liver from UKBB WB on UKBB Indian. Y-axis shows the fraction of cases assigned to each cluster in UKBB WB dataset and UKBB Indian. **d.** Comparison with CARDIoGRAM clustering projection. Y-axis shows the difference in fraction of cases between the external cohort into which the clustering was projected (CARDIoGRAM or UKBB Indian) and the model clustering cohort (UKBB WB). For CARDIoGRAM, average across 9 cohorts +/- standard deviation (error bars) is displayed. **e.** For each group, Spearman correlation of WMW estimates in UKBB WB and the external cohorts (CARDIoGRAM and UKBB Indian) only from genes that are significantly associated with that group across all tissues. For CARDIoGRAM, average across 9 cohorts +/- standard deviation (error bars) is displayed.

Tissue	N of samples	N of genes	N of prior features	N of reliable genes	N of reg- SNPs	Percentage of reg- SNPs with Prior	Percentage of reg- SNPs in DHS
Dorsolateral Prefrontal Cortex	478	15578	15	6854	366706	36.65	NA
Adipose Subcutaneous	242	25971	3	6058	423635	25.85	34.63
Adipose Visceral Omentum	164	25139	3	3910	386744	27.68	32.01
Adrenal Gland	105	23624	1	3027	377947	23.50	32.18
Artery Aorta	185	24274	7	5277	402688	38.45	33.31
Artery Coronary	99	23880	7	2298	343528	39.24	33.41
Artery Tibial	239	24335	7	5918	364109	41.93	34.86
Brain Caudate basal ganglia	90	24512	15	2635	349538	39.59	34.46
Brain Cerebellar Hemisphere	77	23762	15	2941	393519	39.13	34.69
Brain Cerebellum	93	24570	15	3788	429782	36.47	33.85
Brain Cortex	81	24110	15	2501	368497	38.62	34.66
Brain Frontal Cortex BA9	77	23765	15	2041	372502	38.05	34.19
Brain Hippocampus	74	23723	15	1671	313967	43.17	36.49
Brain Hypothalamus	72	24426	15	1565	342292	37.26	33.86
Brain Nucleus accumbens basal_ganglia	81	24386	15	2290	341053	36.89	33.16
Cells EBV-transformed lymphocytes	94	21779	2	2706	372078	26.15	31.63
Colon Sigmoid	118	24051	8	2925	379960	33.05	35.08
Colon Transverse	145	25354	8	3522	374357	30.48	33.25
Esophagus Gastroesophageal Junction	115	23575	8	3030	346204	28.65	32.55
Esophagus Mucosa	224	25038	8	6107	381943	31.00	34.21
Esophagus Muscularis	199	24360	8	5754	379200	29.50	32.87
Heart Atrial Appendage	151	23666	7	2733	511496	33.77	32.41
Heart Left Ventricle	172	22681	7	3628	294768	45.07	36.77
Liver	94	22158	2	2215	306512	32.95	33.31
Lung	241	27372	1	5749	399559	20.40	31.66
Muscle Skeletal	297	22942	2	5566	292706	33.73	36.10
Pancreas	132	23153	1	3631	361244	22.70	32.41
Skin Not Sun Exposed Suprapubic	173	25922	1	4740	407576	13.36	30.82
Skin Sun Exposed Lower leg	252	26582	1	6614	427755	13.79	31.33
Small Intestine Terminal Ileum	74	25010	8	1594	500251	28.62	32.89
Spleen	79	24354	1	2556	442687	19.90	32.35
Stomach	144	24861	8	3215	339228	29.71	33.23
Thyroid	233	27305	1	7447	434307	18.44	31.73
Whole Blood	280	22805	6	4644	279175	35.69	35.75

Supplementary Table 1. Summary of tissue-specific gene expression models via PriLer.

Summary of tissue specific gene-expression models in terms of number of samples, genes, prior

feature applied, reliable genes, regulatory variants (reg-SNPs), percentage of reg-SNPs intersecting a prior used in the model and a DNase I hypersensitive sites (DHS) in at least 1 biosample.

Loci	N. genes	CAD best Z- statistic	Tissue	Group-specific differences	Best group- specific gene	WMW estimate best gene	WMW p-value best gene
chr1:109.3 -110.5Mb	8	3,4111748 28	Artery_Aorta	gr1,gr2,gr3,gr4,gr5	CELSR2	0.02761,0.02442,- 0.06886,0.02981,- 1.16541	1.99e-36,2.62e-20,2.37e- 104,2.65e-40,3.39e-102
chr1:109.4 -110.5Mb	7	4,9759940 5	Heart_Atrial_A ppendage	gr1,gr2,gr3,gr4,gr5	SYPL2	0.26639,0.24292,- 0.53989,0.27574,- 1.11943	6.45e-84,4.18e-45,2.46e- 290,5.4e-86,3.03e-127

chr1:109.4 -110.4Mb	6	3,3344466 29	Adrenal_Glan d	gr1,gr2,gr3,gr4,gr5	SARS	0.40403,0.3579,- 0.69966,0.44269,- 1.2753	2.33e-127,7.25e- 64,0,1.23e-146,2.05e-235
chr1:109.4 -110.5Mb	6	4,5836182 48	Colon_Sigmoi d	gr1,gr2,gr3,gr4,gr5	CELSR2	0.30218,0.25229,- 0.63743,0.3044,- 1.37487	2.56e-122,4.35e- 58,0,2.92e-116,1.52e-242
chr1:109.4 -110.5Mb	9	- 7,0286640 47	Whole_Blood	gr1,gr2,gr3,gr4,gr5	PSRC1	-0.60816,- 0.51929,1.15011,- 0.58608,2.07084	0,2.69e-167,0,4.81e- 306,0
chr1:109.4 -110.5Mb	6	- 4,5806886 04	Adipose_Subc utaneous	gr1,gr2,gr3,gr4,gr5	RP5- 1065J22.8	-0.25132,- 0.17771,0.48696,- 0.27048,0.97473	3.77e-73,3.24e-24,4.8e- 234,4.11e-81,1.16e-105
chr1:109.6 -110.5Mb	4	- 1,6666391 22	Adipose_Visce ral_Omentum	gr1,gr2,gr3,gr4,gr5	RP4-735C1.4	-0.09594,- 0.12862,0.19399,- 0.12219,0.32612	3.66e-08,7.67e-09,3.59e- 33,8.32e-12,4.36e-18
chr1:109.6 -110.3Mb	6	- 10,009335 09	Liver	gr1,gr2,gr3,gr4,gr5	CELSR2	-0.2424,- 0.12874,1.74223,- 0.2003,3.42219	0,2.58e-259,0,0,0
chr1:109.8 -110.5Mb	6	3,0319888 98	Artery_Corona ry	gr1,gr2,gr3,gr4,gr5	SYPL2	0.13727,0.10924,- 0.26075,0.13562,- 0.60034	3.6e-24,7.55e-11,6.17e- 68,2.29e-22,1.25e-42
chr1:109.8 -110.5Mb	4	- 2,3961832 21	Heart_Left_Ve ntricle	gr1,gr2,gr3,gr4,gr5	SYPL2	0.14649,0.14693,- 0.28754,0.15085,- 0.59976	2.49e-22,1.01e-14,1.12e- 71,8.84e-23,3.53e-44
chr1:109.9 -110.5Mb	3	- 2,2532826 61	Colon_Transv erse	gr1,gr2,gr3,gr4,gr5	AMIGO1	-0.07133,- 0.06855,0.16263,- 0.09108,0.40657	9.36e-11,6.49e-07,3.74e- 35,5.29e-15,1.21e-26
chr2:39.5- 39.9Mb	1	1,2437692 6	Adipose_Subc utaneous	gr2	AC007246.3	-0.03977	1.81e-05
chr2:203.7 -204.1Mb	1	- 7,5643682 15	Artery_Aorta	gr1	NBEAL1	0.00876	7.56e-05
chr4:77.6- 78Mb	1	1,3555106 51	Artery_Corona ry	gr1	SOWAHB	0.00809	2.04e-05
chr5:16.2- 16.6Mb	1	- 0,4308179 75	Heart_Left_Ve ntricle	gr1	RP1- 167G20.1	0.06094	7.27e-05
chr6:25.5- 33.7Mb	68	- 4,3793228 09	Adipose_Visce ral_Omentum	gr1,gr2,gr4	HLA-B	-0.85333,- 0.08019,0.96545	0,2.62e-05,0
chr6:25.5- 33.9Mb	63	- 4,1103281 39	Adrenal_Glan d	gr1,gr2,gr4	HLA-DQB1- AS1	-0.46386,- 0.07382,0.55972	6.9e-198,7.7e-06,1.08e- 256
chr6:25.7- 33.7Mb	50	- 3,9916513 58	Liver	gr1,gr2,gr4	CYP21A2	0.28199,0.08718,- 0.43291	4.89e-67,1.51e-05,2.41e- 112
chr6:25.8- 33.9Mb	82	4,5802484 35	Artery_Aorta	gr1,gr2,gr4	HCG27	0.52707,0.08608,- 0.65365	6.51e-229,1.58e- 05,4.73e-297
chr6:25.8- 33.4Mb	69	4,3126732 04	Colon_Transv erse	gr1,gr2,gr4	HLA-DQB1- AS1	-0.27096,- 0.06134,0.37388	2.42e-112,2.15e- 05,6.71e-159
chr6:25.8- 33.8Mb	73	4,3734130 98	Whole_Blood	gr1,gr2,gr4	HLA-B	-0.78835,- 0.08126.0.92798	0,1.88e-05,0
chr6:25.8- 33.7Mb	76	- 4,7479059 7	Heart_Left_Ve ntricle	gr1,gr2,gr4	HLA-DRB1	-0.18475,- 0.04601,0.281	2.62e-107,1.61e- 06,1.78e-158
chr6:25.8- 33.7Mb	98	- 4,2854597 53	Adipose_Subc utaneous	gr1,gr2,gr4	HLA-B	-0.77594,- 0.08691,0.87628	0,1.99e-05,0
chr6:26- 34Mb	63	4,4873970 64	Colon_Sigmoi d	gr1,gr2,gr4	CYP21A2	0.5061,0.1101,- 0.65137	1.06e-213,5.09e- 08,7.669999999999999 290
chr6:26.2- 28.4Mb	6	- 1,1922999 5	Artery_Corona ry	gr1,gr4	BTN3A2	0.12674,-0.13485	2.23e-55,3.07e-48
chr6:26.2- 33.8Mb	50	- 4,1386611 72	Heart_Atrial_A ppendage	gr1,gr2,gr4	HLA-B	-0.86251,- 0.07401,0.9944	0,1.88e-05,0
chr6:29.4- 34Mb	49	- 3,7512265 77	Artery_Corona ry	gr1,gr2,gr4	HLA-DRB1	-0.13472,- 0.03993,0.28299	1.84e-66,1.94e-07,1.6e- 114
chr8:10.2- 10.6Mb	1	- 1,0681284 46	Adrenal_Glan d	gr1	PRSS51	0.06507	0.000144
chr12:10.9 -11.3Mb	1	- 1,6203816 13	Adipose_Visce ral_Omentum	gr4	TAS2R15	0.02217	0.00016
chr12:58.7 -59.1Mb	1	0,4684165 25	Adipose_Subc utaneous	gr4	RP11-362K2.2	-0.00446	0.000179
chr12:110. 1-110.5Mb	1	- 0,3364592 5	Adipose_Subc utaneous	gr2	GLTP	-0.11059	2.01e-07
chr12:110. 1-110.5Mb	1	- 1,0386371 67	Artery_Corona ry	gr2	GLTP	-0.01984	5.63e-06

chr12:110. 7-112.7Mb	7	- 6,1460024 31	Adipose_Visce ral_Omentum	gr1,gr2,gr4	TMEM116	-0.14798,2.15816,- 0.09355	3.98e-166,0,3.94e-99
chr12:110. 7-113.5Mb	6	- 4,6227362 46	Whole_Blood	gr1,gr2,gr4	TMEM116	-0.20588,2.0451,- 0.17274	3.01e-192,0,2.34e-121
chr12:110. 7-112.7Mb	4	3,7513440 91	Colon_Transv erse	gr1,gr2,gr4	TMEM116	-0.17116,2.00887,- 0.15359	2.3e-139,0,2.81e-103
chr12:111. 2-112.7Mb	6	- 5,8568762 71	Heart_Left_Ve ntricle	gr1,gr2,gr4	RP3-462E2.5	0.31558,- 1.89141,0.22527	4.36e-189,0,3.67e-126
chr12:111. 9-112.7Mb	2	- 6,6447969 97	Liver	gr1,gr2,gr4	TMEM116	-0.07999,2.30002,- 0.06325	8.15e-165,0,2.59e-103
chr12:112- 112.7Mb	5	- 5,4413874 26	Artery_Aorta	gr1,gr2,gr4	TMEM116	-0.10892,1.95019,- 0.0882	1.74e-82,0,4.26e-56
chr12:112- 112.7Mb	4	- 5,0265378 08	Heart_Atrial_A ppendage	gr1,gr2,gr4	ADAM1B	-0.05466,2.40601,- 0.04308	9.02e-211,0,1.93e-132
chr12:112. 1-113.5Mb	6	5,2893887 69	Adipose_Subc utaneous	gr1,gr2,gr4	TMEM116	-0.04571,2.36515,- 0.03551	3.4e-125,0,6.22e-78
chr12:112. 1-113.7Mb	4	- 4,9494561 62	Artery_Corona ry	gr1,gr2,gr4	TMEM116	-0.10179,2.14716,- 0.08338	6.93e-83,0,2.89e-61
chr12:112. 1-113.8Mb	2	3,2311146 58	Adrenal_Glan d	gr1,gr2,gr4	ADAM1A	0.03358,- 1.59637,0.02995	4.79e-46,2.92e- 212,5.79e-37
chr12:112. 1-112.9Mb	3	5,1116835 48	Colon_Sigmoi d	gr1,gr2,gr4	TMEM116	-0.23844,1.90541,- 0.17158	2.65e-163,0,3.29e-99
chr14:24.4 -24.8Mb	1	2,3687233 51	Adrenal_Glan d	gr1	EMC9	-0.00907	0.00012
chr15:28.4 -28.8Mb	1	0,6926708 35	Whole_Blood	gr1	HERC2	-0.00543	2.41e-05
chr15:50.8 -51.2Mb	1	-0,5857644	Artery_Corona ry	gr1	RP11- 507J18.2	-0.00415	0.000214
chr17:7.3- 7.7Mb	1	- 0,0390065 89	Adipose_Subc utaneous	gr1	TNFSF12	0.01924	2.88e-05
chr17:7.3- 7.7Mb	1	1,0455349 27	Colon_Transv erse	gr1	SAT2	-0.02237	5,00E-05
chr17:73.7 -74.1Mb	1	0,4454657 07	Whole_Blood	gr3	TRIM47	-0.03431	1.96e-05
chr20:0.5- 0.9Mb	1	- 0,7277762 28	Adipose_Subc utaneous	gr1	SLC52A3	0.03398	8.95e-05

Suppleemntary Table 2. Group-specific Genes for CAD cases clustering in Liver.

Using the clustering structure of CAD cases from UKBB found in liver, the table reports genes that are significant (FDR 0.01) in at least one group across all tissues, tested via Wilcoxon-Mann-Whitney (WMW) for single a group against remaining cases after normalization. Significance is assessed after tissue-specific and group-specific multiple tested correction via Benjamini-Hochberg procedure. For each tissue, genes are combined into loci based on their genomic position (distance 1Mb of enlarged TSS window \pm 200kb). For each group of genes in a tissue-specific locus, the table shows Z-statistic of the most significant gene for CAD, the groups with significantly different distribution in at least one gene, the common gene across groups with strongest association with a group distribution and the corresponding WMW estimate and p-

value.

UKBiobank Field	UKBiobank Meaning	UKBiobank Field class	Group- specific Test	Beta	SE beta	P- value	P- value BH correct ed	Type phenot ype	OR or Beta	Conf. Int. (Iowe r)	Conf. Int. (uppe r)
Apolipoprotein B	NA	Blood_bioch	gr1 vs all	7.90e-	1.41e-	2.37e-	3.91e-	CONTI	7.90e-	5.13e-	1.07e-
Aspartate	NA	Blood_bioch emistry	gr1_vs_all	02 6.27e- 02	02 1.68e- 02	08 1.90e- 04	06 8.66e- 03	CONTI	02 6.27e- 02	02 2.98e- 02	9.57e- 02
White blood cell (leukocyte) count	NA	Blood_count	gr1_vs_all	6.23e- 02	1.68e- 02	2.00e- 04	8.66e- 03	CONTI NUOUS	6.23e- 02	2.95e- 02	9.52e- 02
Lymphocyte count	NA	Blood_count	gr1_vs_all	6.20e- 02	1.67e- 02	2.10e- 04	8.66e- 03	CONTI NUOUS	6.20e- 02	2.92e- 02	9.47e- 02
LDL direct	NA	Blood_bioch emistry	gr1_vs_all	4.57e- 02	1.31e- 02	4.99e- 04	1.65e- 02	CONTI NUOUS	4.57e- 02	2.00e- 02	7.14e- 02
Cholesterol	NA	Blood_bioch emistry	gr1_vs_all	4.44e- 02	1.32e- 02	7.64e- 04	2.10e- 02	CONTI NUOUS	4.44e- 02	1.85e- 02	7.02e- 02
Eosinophill count	NA	Blood_count	gr1_vs_all	1.07e- 01	3.24e- 02	9.86e- 04	2.32e- 02	CAT_O RD	1.11e+ 00	1.04e +00	1.19e +00
Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones	None of the above	Medication	gr1_vs_all	-2.52e- 01	8.10e- 02	1.85e- 03	3.82e- 02	CAT_M UL_BIN ARY_V AR	7.77e- 01	6.63e- 01	9.11e- 01
Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones	Cholesterol lowering medication	Medication	gr1_vs_all	2.24e- 01	7.30e- 02	2.16e- 03	3.96e- 02	CAT_M UL_BIN ARY_V AR	1.25e+ 00	1.08e +00	1.44e +00
Basophill count	NA	Blood_count	gr1_vs_all	9.62e- 02	3.22e- 02	2.78e- 03	4.58e- 02	CAT_O RD	1.10e+ 00	1.03e +00	1.17e +00
Urate	NA	Blood_bioch emistry	gr1_vs_all	-4.51e- 02	1.59e- 02	4.50e- 03	6.74e- 02	CONTI NUOUS	-4.51e- 02	- 7.63e- 02	- 1.40e- 02
Mean sphered cell volume	NA	Blood_count	gr1_vs_all	-4.76e- 02	1.70e- 02	5.04e- 03	6.93e- 02	CONTI NUOUS	-4.76e- 02	- 8.08e- 02	- 1.43e- 02
Illnesses of siblings	Heart disease	Family_histor y	gr1_vs_all	1.20e- 01	4.44e- 02	7.08e- 03	8.99e- 02	CAT_M UL_BIN ARY_V AR	1.13e+ 00	1.03e +00	1.23e +00
Diagnoses - ICD10	I20 Angina pectoris	ICD9- 10_OPCS4	gr1_vs_all	8.67e- 02	3.34e- 02	9.42e- 03	1.11e- 01	CAT_SI NGLE_ UNORD ERED	1.09e+ 00	1.02e +00	1.16e +00
Apolipoprotein B	NA	Blood_bioch	gr2_vs_all	1.05e-	1.81e-	6.92e-	1.14e- 06		1.05e-	6.92e-	1.40e-
LDL direct	NA	Blood_bioch emistry	gr2_vs_all	7.64e- 02	1.68e- 02	5.19e- 06	4.28e- 04	CONTI	7.64e- 02	4.36e- 02	1.09e- 01
Eosinophill count	NA	Blood_count	gr2_vs_all	-1.48e- 01	4.11e- 02	3.24e- 04	1.78e- 02	CAT_O RD	8.63e- 01	7.96e- 01	9.35e- 01
Types of transport used (excluding work)	Walk	Physical_acti vity	gr2_vs_all	-1.46e- 01	4.37e- 02	8.25e- 04	3.40e- 02	CAT_M UL_BIN ARY_V AR	8.64e- 01	7.93e- 01	9.41e- 01
Cholesterol	NA	Blood_bioch emistry	gr2_vs_all	5.50e- 02	1.69e- 02	1.11e- 03	3.66e- 02	CONTI NUOUS	5.50e- 02	2.20e- 02	8.81e- 02
Aspartate aminotransferase	NA	Blood_bioch emistry	gr2_vs_all	-6.78e- 02	2.15e- 02	1.60e- 03	4.39e- 02	CONTI NUOUS	-6.78e- 02	- 1.10e- 01	- 2.57e- 02
Medication for pain relief, constipation, heartburn	Omeprazole (e.g. Zanprol)	Medication	gr2_vs_all	1.83e- 01	5.88e- 02	1.87e- 03	4.41e- 02	CAT_M UL_BIN ARY_V AR	1.20e+ 00	1.07e +00	1.35e +00
Reticulocyte count	NA	Blood_count	gr2_vs_all	-6.43e- 02	2.13e- 02	2.58e- 03	5.04e- 02	CONTI NUOUS	-6.43e- 02	- 1.06e- 01	- 2.25e- 02
Haemoglobin concentration	NA	Blood_count	gr2_vs_all	-5.67e- 02	1.89e- 02	2.75e- 03	5.04e- 02	CONTI NUOUS	-5.67e- 02	- 9.38e- 02	- 1.96e- 02

Eosinophill percentage	NA	Blood_count	gr2_vs_all	-6.32e- 02	2.15e- 02	3.33e- 03	5.50e- 02	CONTI NUOUS	-6.32e- 02	- 1.05e- 01	- 2.10e- 02
Alkaline phosphatase	NA	Blood_bioch emistry	gr2_vs_all	-6.04e- 02	2.15e- 02	4.97e- 03	7.46e- 02	CONTI NUOUS	-6.04e- 02	- 1.02e- 01	- 1.83e- 02
Reticulocyte percentage	NA	Blood_count	gr2_vs_all	-5.84e- 02	2.14e- 02	6.32e- 03	8.69e- 02	CONTI NUOUS	-5.84e- 02	- 1.00e- 01	- 1.65e- 02
Haematocrit percentage	NA	Blood_count	gr2_vs_all	-5.18e- 02	1.93e- 02	7.35e- 03	8.98e- 02	CONTI NUOUS	-5.18e- 02	- 8.96e- 02	- 1.39e- 02
Diagnoses - ICD10	I20 Angina pectoris	ICD9- 10_OPCS4	gr2_vs_all	1.14e- 01	4.27e- 02	7.62e- 03	8.98e- 02	CAT_SI NGLE_ UNORD ERED	1.12e+ 00	1.03e +00	1.22e +00
Neutrophill percentage	NA	Blood_count	gr2_vs_all	5.61e- 02	2.14e- 02	8.74e- 03	9.61e- 02	CONTI NUOUS	5.61e- 02	1.42e- 02	9.81e- 02
Apolipoprotein B	NA	Blood_bioch emistry	gr3_vs_all	-1.28e- 01	1.33e- 02	5.58e- 22	9.21e- 20	CONTI NUOUS	-1.28e- 01	- 1.54e- 01	- 1.02e- 01
LDL direct	NA	Blood_bioch emistry	gr3_vs_all	-7.40e- 02	1.23e- 02	2.13e- 09	1.76e- 07	CONTI NUOUS	-7.40e- 02	- 9.82e- 02	- 4.98e- 02
Cholesterol	NA	Blood_bioch emistry	gr3_vs_all	-5.34e- 02	1.24e- 02	1.69e- 05	9.31e- 04	CONTI NUOUS	-5.34e- 02	- 7.78e- 02	- 2.91e- 02
Apolipoprotein A	NA	Blood_bioch emistry	gr3_vs_all	6.50e- 02	1.57e- 02	3.48e- 05	1.44e- 03	CONTI NUOUS	6.50e- 02	3.43e- 02	9.58e- 02
Medication for cholesterol, blood pressure or diabotos	Cholesterol lowering medication	Medication	gr3_vs_all	-1.35e- 01	3.89e- 02	5.42e- 04	1.79e- 02	CAT_M UL_BIN ARY_V	8.74e- 01	8.10e- 01	9.43e- 01
HDL cholesterol	NA	Blood_bioch	gr3_vs_all	4.22e-	1.54e-	6.33e-	1.74e-		4.22e-	1.19e-	7.25e-
Apolipoprotein B	NA	Blood_bioch emistry	gr4_vs_all	6.55e- 02	1.45e- 02	6.50e- 06	1.07e- 03	CONTI NUOUS	6.55e- 02	3.70e- 02	9.39e- 02
Apolipoprotein A	NA	Blood_bioch emistry	gr4_vs_all	-6.36e- 02	1.71e- 02	1.97e- 04	1.63e- 02	CONTI NUOUS	-6.36e- 02	- 9.71e-	- 3.01e-
Medication for pain relief, constipation, heartburn	Paracetamol	Medication	gr4_vs_all	-1.41e- 01	4.26e- 02	9.68e- 04	4.09e- 02	CAT_M UL_BIN ARY_V AR	8.69e- 01	7.99e- 01	9.44e- 01
Medication for cholesterol, blood pressure or diabetes	Cholesterol lowering medication	Medication	gr4_vs_all	1.42e- 01	4.32e- 02	9.92e- 04	4.09e- 02	CAT_M UL_BIN ARY_V AR	1.15e+ 00	1.06e +00	1.25e +00
C-reactive protein	NA	Blood_bioch emistry	gr4_vs_all	-5.47e- 02	1.71e- 02	1.42e- 03	4.69e- 02	CONTI NUOUS	-5.47e- 02	- 8.82e- 02	- 2.11e- 02
Non-oily fish intake	NA	Diet	gr4_vs_all	-9.46e- 02	3.27e- 02	3.78e- 03	1.04e- 01	CAT_O RD	9.10e- 01	8.53e- 01	9.70e- 01
LDL direct	NA	Blood_bioch emistry	gr4_vs_all	3.76e- 02	1.35e- 02	5.21e- 03	1.23e- 01	CONTI NUOUS	3.76e- 02	1.12e- 02	6.40e- 02
HDL cholesterol	NA	Blood_bioch emistry	gr4_vs_all	-4.43e- 02	1.68e- 02	8.33e- 03	1.72e- 01	CONTI NUOUS	-4.43e- 02	- 7.73e- 02	- 1.14e- 02
Apolipoprotein B	NA	Blood_bioch emistry	gr5_vs_all	-2.92e- 01	3.10e- 02	4.19e- 21	6.92e- 19	CONTI NUOUS	-2.92e- 01	- 3.53e- 01	- 2.32e- 01
LDL direct	NA	Blood_bioch emistry	gr5_vs_all	-2.16e- 01	2.88e- 02	6.33e- 14	5.22e- 12	CONTI NUOUS	-2.16e- 01	- 2.73e- 01	- 1.60e- 01
Cholesterol	NA	Blood_bioch emistry	gr5_vs_all	-2.00e- 01	2.90e- 02	5.11e- 12	2.81e- 10	CONTI NUOUS	-2.00e- 01	- 2.57e- 01	- 1.43e- 01
Diagnoses - ICD10	E78 Disorders of lipoprotein metabolism and other lipidaemias	ICD9- 10_OPCS4	gr5_vs_all	-2.87e- 01	7.34e- 02	9.46e- 05	3.90e- 03	CAT_SI NGLE_ UNORD ERED	7.51e- 01	6.50e- 01	8.67e- 01
Medication for cholesterol, blood pressure, diabetes, or take exogenous hormones	Cholesterol lowering medication	Medication	gr5_vs_all	-5.83e- 01	1.56e- 01	1.82e- 04	6.02e- 03	CAT_M UL_BIN ARY_V AR	5.58e- 01	4.11e- 01	7.58e- 01
Mean sphered cell volume	NA	Blood_count	gr5_vs_all	1.33e- 01	3.76e- 02	4.00e- 04	1.10e- 02	CONTI NUOUS	1.33e- 01	5.94e- 02	2.07e- 01
Medication for cholesterol, blood pressure,	None of the above	Medication	gr5_vs_all	5.33e- 01	1.56e- 01	6.36e- 04	1.50e- 02	CAT_M UL_BIN	1.70e+ 00	1.26e +00	2.31e +00

diabetes, or take exogenous hormones								ARY_V AR			
Direct bilirubin	NA	Blood_bioch emistry	gr5_vs_all	1.21e- 01	3.77e- 02	1.34e- 03	2.77e- 02	CONTI NUOUS	1.21e- 01	4.70e- 02	1.95e- 01
Medication for cholesterol, blood pressure or diabetes	Cholesterol lowering medication	Medication	gr5_vs_all	-2.80e- 01	8.97e- 02	1.77e- 03	3.24e- 02	CAT_M UL_BIN ARY_V AR	7.55e- 01	6.34e- 01	9.01e- 01
Diagnoses - ICD10	I26 Pulmonary embolism	ICD9- 10_OPCS4	gr5_vs_all	5.62e- 01	1.93e- 01	3.61e- 03	5.96e- 02	CAT_SI NGLE_ UNORD ERED	1.75e+ 00	1.20e +00	2.56e +00
Illnesses of siblings	High blood pressure	Family_histor y	gr5_vs_all	-2.76e- 01	9.87e- 02	5.10e- 03	7.52e- 02	CAT_M UL_BIN ARY_V AR	7.59e- 01	6.25e- 01	9.20e- 01
Eosinophill percentage	NA	Blood_count	gr5_vs_all	-1.03e- 01	3.74e- 02	5.88e- 03	7.52e- 02	CONTI NUOUS	-1.03e- 01	- 1.76e- 01	- 2.97e- 02
Diagnoses - ICD10	I20 Angina pectoris	ICD9- 10_OPCS4	gr5_vs_all	-2.02e- 01	7.34e- 02	5.92e- 03	7.52e- 02	CAT_SI NGLE_ UNORD ERED	8.17e- 01	7.08e- 01	9.44e- 01
Medication for pain relief, constipation, heartburn	Aspirin	Medication	gr5_vs_all	-2.03e- 01	7.56e- 02	7.15e- 03	7.98e- 02	CAT_M UL_BIN ARY_V AR	8.16e- 01	7.03e- 01	9.46e- 01
Albumin	NA	Blood_bioch emistry	gr5_vs_all	-1.03e- 01	3.84e- 02	7.25e- 03	7.98e- 02	CONTI NUOUS	-1.03e- 01	- 1.79e- 01	- 2.79e- 02

Supplementary Table 3. Differences in endophenotypes for groups of CAD cases in Liver.

Group-specific endophenotype analysis using clustering of CAD cases in liver from UKBB with nominal p-value < 0.01. The tested endophenotypes are CAD related classes from UKBB. Differences are tested via Generalized Linear Model (GLM) with phenotype the dependent variable and group-specific clustering structure (gr_i versus remaining cases) and covariates the independent variables. The regression coefficient β estimate, standard error and p-value refer to the grouping variable, estimates are corrected for multiple testing in a group-specific manner using Benjamini-Hochberg procedure. The family for GLM applied depends on the phenotype nature (continuous, binary or categorical ordinal). For non-continuous ones it is shown odds ratio and the corresponding 95% confidence interval, for continuous ones instead confidence intervals refer to β estimates.

Dataset	ID	Group- specific Test	Beta	SE Beta	P-value	Type phenotype	OR or Beta	Conf. Int. (lower)	Conf. Int. (upper)	empirical P-value
GerMIFSV	Vessel_affected	gr1_vs_all	0,22824 3267	0,08800 6103	0,00955 9527	CAT_ORD	1,25639 0927	1,05733 8048	1,49291 7203	NA
UK Biobank	Chronic_kidney_d isease	gr1_vs_all	- 0,11917 8911	0,06423 4066	0,06354 1295	CAT_SINGL E_UNORDE RED	0,88764 8977	0,78264 555	1,00674 0159	0,012
UK Biobank	Chronic_obstructi ve_pulmonary_dis ease	gr1_vs_all	- 0,10158 7954	0,05623 3154	0,07083 2608	CAT_SINGL E_UNORDE RED	0,90340 1718	0,80912 4152	1,00866 4321	0,004
UK Biobank	Coronary_artery_ bypass_graft	gr1_vs_all	0,07025 7944	0,04241 8882	0,09766 3229	CAT_SINGL E_UNORDE RED	1,07278 4864	0,98720 1075	1,16578 82	0,008
UK Biobank	Smoking	gr2_vs_all	- 0,13048 7812	0,04640 3812	0,00492 3354	CAT_SINGL E_UNORDE RED	0,87766 719	0,80136 5916	0,96123 3415	0,016
UK Biobank	UAP	gr2_vs_all	0,13984 3208	0,05337 0622	0,00878 7095	CAT_SINGL E_UNORDE RED	1,15009 3459	1,03586 6952	1,27691 5883	0,004
UK Biobank	Hyperlipidemia	gr2_vs_all	0,09513 2326	0,04287 2399	0,02648 9149	CAT_SINGL E_UNORDE RED	1,09980 4379	1,01116 5846	1,19621 2942	0,008
UK Biobank	Acute_MI	gr2_vs_all	- 0,07836 7963	0,04345 3883	0,07131 3752	CAT_SINGL E_UNORDE RED	0,92462 4136	0,84913 5922	1,00682 3256	0,008
UK Biobank	Cerebrovascular_ disease	gr2_vs_all	0,51983 3253	0,29199 1541	0,07502 6478	CAT_SINGL E_UNORDE RED	1,68174 72	0,94889 2607	2,98060 4574	0
UK Biobank	Age_stroke	gr2_vs_all	1,15897 1426	0,66916 1436	0,08360 8026	CONTINUO US	1,15897 1426	- 0,15256 089	2,47050 3741	0,004
UK Biobank	Age_stroke	gr3_vs_all	- 1,33238 0178	0,49530 4904	0,00727 224	CONTINUO US	- 1,33238 0178	- 2,30315 9951	- 0,36160 0404	0,004
UK Biobank	Chronic_obstructi ve_pulmonary_dis ease	gr3_vs_all	0,13130 8416	0,05064 7758	0,00952 5873	CAT_SINGL E_UNORDE RED	1,14031 942	1,03255 9463	1,25932 542	0,004
UK Biobank	Hyperlipidemia	gr3_vs_all	- 0,08040 1614	0,03134 2123	0,01030 898	CAT_SINGL E_UNORDE RED	0,92274 5684	0,86776 7856	0,98120 6658	0,008
UK Biobank	Peripheral_vascul ar_disease	gr3_vs_all	- 0,26081 2053	0,11940 0731	0,02893 7114	CAT_SINGL E_UNORDE RED	0,77042 5705	0,60967 26	0,97356 4773	0,008
UK Biobank	Age_heart_attack	gr3_vs_all	0,33555 7819	0,17807 8086	0,05955 7749	CONTINUO US	0,33555 7819	- 0,01346 8817	0,68458 4455	0,004
UK Biobank	Smoking	gr3_vs_all	0,06464 1379	0,03497 599	0,06457 8568	CAT_SINGL E_UNORDE RED	1,06677 6387	0,99609 7333	1,14247 0543	0,016
UK Biobank	Coronary_artery_ bypass_graft	gr3_vs_all	- 0,07223 3624	0,04055 3764	0,07488 2763	CAT_SINGL E_UNORDE RED	0,93031 3527	0,85923 0944	1,00727 6639	0,008
GerMIFSV	Gensini_score	gr3_vs_all	- 0,07311 755	0,04297 6882	0,08901 3944	CONTINUO US	- 0,07311 755	- 0,15735 069	0,01111 5591	NA
UK Biobank	Peripheral_vascul ar_disease	gr4_vs_all	0,38164 915	0,11425 1454	0,00083 6483	CAT_SINGL E_UNORDE RED	1,46469 8106	1,17083 88	1,83231 0769	0,008
UK Biobank	Age_stroke	gr4_vs_all	1,18338 4837	0,52952 493	0,02566 5976	CONTINUO US	1,18338 4837	0,14553 5046	2,22123 4628	0,004
UK Biobank	Poor_mobility	gr4_vs_all	- 0,69897 3328	0,34065 7765	0,04018 5757	CAT_SINGL E_UNORDE RED	0,49709 5396	0,25495 9575	0,96918 8284	0,012
UK Biobank	UAP	gr4_vs_all	- 0,09060 8124	0,04490 2955	0,04360 5271	CAT_SINGL E_UNORDE RED	0,91337 5571	0,83642 6776	0,99740 3428	0,004
UK Biobank	Age_heart_attack	gr4_vs_all	- 0,35936 7995	0,19585 0066	0,06655 6719	CONTINUO US	- 0,35936 7995	- 0,74322 7071	0,02449 108	0,004
UK Biobank	Coronary_artery_ bypass_graft	gr4_vs_all	0,07280 4504	0,04341 6156	0,09356 2253	CAT_SINGL E_UNORDE RED	1,07552 0257	0,98778 5611	1,17104 7452	0,008
UK Biobank	Age_angina	gr4_vs_all	- 0,32269 4619	0,19583 605	0,09944 6041	CONTINUO US	- 0,32269 4619	- 0,70652 6223	0,06113 6986	0,008
UK Biobank	Hyperlipidemia	gr5_vs_all	- 0,28670 8045	0,07343 6728	9,46E- 05	CAT_SINGL E_UNORDE RED	0,75073 0876	0,65009 2	0,86694 9368	0,008
UK Biobank	Coronary_artery_ bypass_graft	gr5_vs_all	- 0,19935 7064	0,10016 4947	0,04655 9249	CAT_SINGL E_UNORDE RED	0,81925 7314	0,67322 4279	0,99696 7232	0,008

UK Biobank	UAP	gr5_vs_all	- 0,18826 7582	0,10082 9004	0,06187 4126	CAT_SINGL E_UNORDE RED	0,82839 3015	0,67984 6122	1,00939 7516	0,004
UK Biobank	T1D	gr5_vs_all	0,31753 0053	0,18301 7205	0,08274 5448	CAT_SINGL E_UNORDE RED	1,37373 0529	0,95965 9182	1,96646 4349	0
UK Biobank	Transient_cerebra I_ischaemic_attac ks	gr5_vs_all	- 0,51600 4502	0,30803 5442	0,09390 5486	CAT_SINGL E_UNORDE RED	0,59690 0705	0,32636 37	1,09169 7551	0,004

Supplementary Table 4. Hypothesis-driven endophenotype differences for CAD cases clustering in Liver.

Group-specific clinical variables analysis using clustering of CAD cases in liver with nominal pvalue < 0.1. For UKBB dataset, clustering of CAD cases in UKBB is considered and 33 clinical variables in UKBB are used without PHESANT preprocessing. For GerMIFSV dataset, clustering structure is obtained via projection from UKBB model clustering and 2 severeness index annotated for that dataset are tested. Differences are tested via Generalized Linear Model (GLM) with phenotype the dependent variable and group-specific clustering structure (gr_i versus remaining cases) and covariates the independent variables. The regression coefficient β estimate, standard error and p-value refer to the grouping variable. The family for GLM applied depends on the phenotype nature (continuous, binary or categorical ordinal). For non-continuous ones it is shown odds ratio and the corresponding 95% confidence interval, for continuous ones instead confidence intervals refer to β estimates. Empirical p-value are computed for UKBB variables comparing to endophenotype associations of random clustering repetitions.

Loci	N. gene s	SCZ best Z- statistic	Tissue	Group- specific differences	Best group- specific gene	WMW estimate best gene	WMW p-value best gene
chr1:27.5-27.9Mb	1	0,60937257	Brain_Cerebellar_ Hemisphere	gr1	CD164L2	0.00634	1.28e-06
chr1:173.4- 173.8Mb	1	4,119438257	Brain_Nucleus_ac cumbens_basal_g anglia	gr2	ANKRD45	0.00336	8.29e-05
chr2:47.4-47.8Mb	1	-1,839532387	DLPC_CMC	gr2	MSH2	0.00784	8.23e-05
chr2:71.2-71.6Mb	1	0,352047327	DLPC_CMC	gr2,gr3	MPHOSPH10	-0.01966,0.01665	2.85e- 07,1.47e-05
chr2:74.9-75.3Mb	1	-0,396267195	Brain_Cerebellar_ Hemisphere	gr1	AC104135.3	0.06489	9.91e-05
chr2:74.9-75.3Mb	1	-0,283647674	Brain_Frontal_Co rtex_BA9	gr1	AC104135.3	0.06382	0.000185
chr2:74.9-75.4Mb	3	0,412348847	Cells_EBV- transformed_lymp hocytes	gr1	AC104135.2	0.06891	3.77e-05
chr2:75-75.4Mb	1	-0,049025121	Brain_Caudate_b asal_ganglia	gr1	AC104135.4	0.06252	0.000142
chr2:135.6- 136.5Mb	2	-0,94314726	DLPC_CMC	gr1	R3HDM1	0.01065	2.05e-06
chr2:224.6-225Mb	1	-1,095143595	DLPC_CMC	gr3	WDFY1	-0.01318	6.19e-08
chr2:224.6-225Mb	1	-0,52061301	Brain_Frontal_Co rtex_BA9	gr3	WDFY1	-0.0439	5.89e-05
chr2:224.6-225Mb	1	1,048818956	Brain_Caudate_b asal_ganglia	gr3	AC073641.2	0.0565	3.87e-05
chr2:224.6-225Mb	1	1,194117805	Cells_EBV- transformed_lymp hocytes	gr3	AC073641.2	0.05246	0.000183
chr3:52.2-52.6Mb	1	-0,202460363	Brain_Cerebellum	gr1	DNAH1	0.01081	0.000164
chr3:110.6-111Mb	1	-1,387956414	DLPC_CMC	gr1	PVRL3	0.00597	2.43e-10
chr3:159.9- 160.3Mb	1	0,804017528	Cells_EBV- transformed_lymp hocytes	gr1	SMC4	-0.0169	9.73e-05
chr6:24.4-34Mb	84	9,11792427	DLPC_CMC	gr1,gr2,gr3	C4A	-2.31284,0.17878,0.14103	0,7.58e- 269,8.64e-177
chr6:24.8-26.9Mb	8	7,492574253	Cells_EBV- transformed_lymp hocytes	gr1,gr2,gr3	BTN3A2	-0.67175,0.09297,0.09251	0,3.02e- 71,1.12e-66
chr6:24.9-33.7Mb	44	-8,509690388	Brain_Cortex	gr1,gr2,gr3	NOTCH4	-1.91242,0.31281,0.28497	0,8.54e- 243,4.19e-221
chr6:25-34Mb	50	-8,765027816	Brain_Caudate_b asal_ganglia	gr1,gr2,gr3	IER3	2.10795,-0.08578,-0.08574	0,5.48e- 216,1.74e-209
chr6:25.8-34Mb	65	9,15699547	Brain_Cerebellar_ Hemisphere	gr1,gr2,gr3	C4A	-2.20347,0.24164,0.27126	0,3e- 219,8.82e-292
chr6:25.8-34Mb	84	8,567758457	Brain_Cerebellum	gr1,gr2,gr3	C4A	-2.0414,0.35472,0.33328	0,4.58e- 267,2.43e-248
chr6:25.8-28.5Mb	11	-7,45033741	Brain_Nucleus_ac cumbens_basal_g anglia	gr1,gr2,gr3	RP1-265C24.5	-1.54759,-0.12148,1.60438	0,0,0
chr6:25.8-33.6Mb	44	-9,091302526	Brain_Frontal_Co rtex_BA9	gr1,gr2,gr3	HLA-DMA	1.7991,-0.17079,-0.14477	0,1.66e- 159,1.1e-115
chr6:25.9-34Mb	43	9,425298026	Brain_Hypothala mus	gr1,gr2,gr3	NCR3	1.93175,-0.12358,-0.09018	0,2.71e- 253,3.42e-155
chr6:26-28.5Mb	8	-7,548006867	Brain_Hippocamp us	gr1,gr2,gr3	AL022393.7	0.76927,1.15978,-1.59026	0,0,0
chr6:27.9-34Mb	51	9,140860601	Cells_EBV- transformed_lymp hocytes	gr1,gr2,gr3	C4A	-2.31136,0.18873,0.20019	0,3.3e- 236,1.9e-287
chr6:29.6-33.6Mb	26	9,479578005	Brain_Hippocamp us	gr1,gr2,gr3	CYP21A1P	-2.1219,0.2312,0.26086	0,2.6e- 215,8.8e-280
chr6:29.6-33.6Mb	31	-8,516985031	Brain_Nucleus_ac cumbens_basal_g anglia	gr1,gr2,gr3	XXbac- BPG300A18.13	1.85146,-0.37392,-0.31261	0,1.39e- 252,3.66e-189
chr6:83.7-84.1Mb	1	-2,688743063	Brain_Cerebellar_ Hemisphere	gr2	RWDD2A	-0.00957	4.68e-05
chr7:5.4-5.8Mb	1	1,539685934	Brain_Hippocamp us	gr3	FSCN1	-0.05445	8.72e-05
chr7:91.7-92.1Mb	1	-0,96554596	Brain_Cerebellum	gr1,gr3	KRIT1	0.00678,-0.00481	7.45e- 07,1.22e-05
chr9:88.2-88.6Mb	1	-0,017199499	DLPC_CMC	gr3	RP11-213G2.3	0.01069	3.29e-07
chr10:97.2- 97.6Mb	1	-1,618003931	Brain_Cerebellum	gr1	ALDH18A1	0.07352	2.6e-05
chr11:61-61.4Mb	1	0,215306172	DLPC_CMC	gr1	TMEM216	-0.00411	2.89e-05
chr11:73.3- 73.7Mb	1	2,671221059	Brain_Cerebellar_ Hemisphere	gr2	MRPL48	0.00619	0.000106
chr12:56.5-	1	1,371344018	Brain_Hypothala	gr1	RP11-	0.00557	8.43e-05
chr12:104.1- 104.5Mb	1	-1,360871384	Brain_Cortex	gr1	MIR3652	-0.00802	6.05e-05

chr12:132.9- 133.3Mb	1	-1,001149867	Brain_Cerebellar_ Hemisphere	gr1	FBRSL1	0.01188	0.000132
chr13:20-20.4Mb	1	0,868280955	Cells_EBV- transformed_lymp hocytes	gr1	MPHOSPH8	0.0077	5.07e-05
chr13:24.3- 24.7Mb	1	1,28914845	Brain_Cerebellar_ Hemisphere	gr1	MIPEP	0.05857	9.67e-05
chr13:79.8- 80.2Mb	1	-0,325824917	Brain_Cerebellum	gr2	RBM26-AS1	0.00716	0.000118
chr14:50.7- 51.1Mb	1	-0,247051358	Brain_Cerebellum	gr2	CDKL1	0.03716	0.000197
chr15:65.5- 65.9Mb	1	-1,264254803	DLPC_CMC	gr2	IGDCC4	0.0499	9.84e-05
chr16:30.2- 30.6Mb	1	-2,104837054	Brain_Hypothala mus	gr3	ZNF48	0.01108	7.79e-05
chr16:67.3- 67.7Mb	1	-2,598944984	Brain_Hippocamp us	gr1	HSD11B2	-0.00499	0.000204
chr16:77-77.4Mb	1	0,330733192	Brain_Cerebellum	gr2	SYCE1L	0.05207	0.000219
chr16:77-77.4Mb	1	-0,159949579	Brain_Frontal_Co rtex_BA9	gr2	SYCE1L	0.01571	0.000203
chr17:18.9- 19.3Mb	1	1,04212852	DLPC_CMC	gr2	SNORD3A	0.00429	5.95e-05
chr19:2-2.4Mb	1	-0,841315918	Brain_Nucleus_ac cumbens_basal_g anglia	gr1	SF3A2	-0.007	2.09e-14
chr19:44.8- 45.2Mb	1	0,760791203	Brain_Hypothala mus	gr2	ZNF180	-0.02512	0.000113
chr21:47.4- 47.8Mb	1	-1,891164482	Brain_Nucleus_ac cumbens_basal_g anglia	gr2	FTCD	-0.03959	5.26e-05
chr21:47.5- 47.9Mb	1	-1,110019041	Brain_Cerebellum	gr2,gr3	MCM3AP	-0.05892,0.05559	1.81e- 05,5.48e-05
chr22:21.8- 22.2Mb	1	2,21030452	Cells_EBV- transformed_lymp hocytes	gr2	YDJC	0.00947	3.52e-05
chr22:22.1- 22.5Mb	1	-1,136840537	Brain_Cerebellar_ Hemisphere	gr3	PPM1F	0.02444	0.000164

Supplementary Table 5. Group-specific Genes for SCZ cases clustering in Dorsolateral prefrontal cortex.

Using the clustering structure of SCZ cases found in DLPC, the table reports genes that are significant in at least one group across all tissues (FDR 0.01), tested via Wilcoxon-Mann-Whitney (WMW) for single a group against remaining cases after concatenation and normalization of 35 SCZ cohorts. Significance is assessed after tissue-specific and group-specific multiple tested correction via Benjamini-Hochberg procedure. For each tissue, genes are combined into loci based on their genomic position (distance 1Mb of enlarged TSS window ± 200kb). For each group of genes in a tissue-specific locus, the table shows Z-statistic of the most significant gene for SCZ, the groups with significantly different distribution in at least one gene, the common gene across groups with strongest association with a group distribution and the corresponding WMW estimate and p-value.

Macro	UKBioba nk Class	UKBioba nk Field	UKBioba nk Meaning	CRM	Group- specific Test	Beta	SE Beta	P-value	P-value BH corrected	Conf. Int. (lower)	Conf. Int. (upper)
	Blood_co unt	White blood cell (leukocyte) count	NA	6215,194 6	gr1_vs_all	- 0,429696 4	0,016630 125	4,12E-145	2,06E-142	- 0,462290 845	- 0,397101 955
	Blood_co unt	Red blood cell (erythrocy te) count	NA	966,0454 93	gr1_vs_all	- 0,070507 801	0,016874 932	2,95E-05	0,000109 204	- 0,103582 061	- 0,037433 541
	Blood_co unt	Haemoglo bin concentrat ion	NA	2167,899 44	gr1_vs_all	- 0,193736 284	0,016826 393	1,37E-30	1,37E-28	- 0,226715 408	0,160757 16
	Blood_co unt	Haematoc rit percentag e	NA	1664,150 71	gr1_vs_all	- 0,157496 525	0,016841 135	9,38E-21	4,47E-19	- 0,190504 542	- 0,124488 507
	Blood_co unt	Mean corpuscul ar volume Mean	NA	1389,440 82	gr1_vs_all	- 0,073763 607	0,016875 434	1,24E-05	5,05E-05	- 0,106838 85	- 0,040688 364
	Blood co unt	corpuscul ar haemoglo bin	NA	1941,678 65	gr1_vs_all	0,103446 856	0,016863 294	8,69E-10	9,65E-09	0,136498 305	0,070395 408
	Blood_co unt	Mean corpuscul ar haemoglo bin concentrat ion	NA	891,8828 49	gr1_vs_all	0,135407 535	0,016848 677	9,68E-16	2,76E-14	0,168430 334	0,102384 735
	Blood_co unt	Red blood cell (erythrocy te) distributio n width	NA	2960,837 29	gr1_vs_all	0,165192 699	0,016838 319	1,13E-22	5,63E-21	0,132190 2	0,198195 198
	Blood_co unt	Platelet count	NA	3413,395 61	gr1_vs_all	- 0,183125 728	0,016826 197	1,62E-27	1,08E-25	- 0,216104 469	- 0,150146 987
	Blood_co unt	Platelet crit	NA	3709,905 52	gr1_vs_all	- 0,230277 839	0,016805 408	1,45E-42	1,81E-40	- 0,263215 833	- 0,197339 845
	Blood_co unt	Platelet distributio n width	NA	1600,104 93	gr1_vs_all	0,101245 965	0,016876 212	2,01E-09	2,05E-08	0,068169 198	0,134322 732
	Blood_co unt	Lymphocy te count	NA	6154,964 97	gr1_vs_all	- 0,434440 564	0,016612 48	1,51E-148	1,51E-145	- 0,467000 426	- 0,401880 701
	Blood_co unt	Monocyte count	NA	3199,605 29	gr1_vs_all	0,225478 206	0,016816 392	7,74E-41	8,60E-39	- 0,258437 729	- 0,192518 682
	Blood_co unt	Neutrophil I count	NA	4303,247 35	gr1_vs_all	0,319768 82	0,016747 06	1,22E-80	3,04E-78	0,352592 455	0,286945 185
	Blood co unt	Eosinophil I count	NA	3856,984 93	gr1_vs_all	0,316434 279	0,016739 838	4,36E-79	8,73E-77	0,349243 758	0,283624 799
	Blood_co unt	Basophill count	NA	647,7254 12	gr1_vs_all	0,115564 617	0,016849 513	7,13E-12	1,15E-10	0,148589 055	0,082540 18
	Blood_co unt	te percentag e	NA	1249,271 98	gr1_vs_all	- 0,100746 387	0,016865 119	2,35E-09	2,31E-08	- 0,133801 412	- 0,067691 362
	Blood_co unt	Monocyte percentag e	NA	1593,071 32	gr1_vs_all	0,115599 375	0,016852 674	7,09E-12	1,15E-10	0,082568 74	0,148630 009
	Blood_co unt	Neutrophil I percentag e	NA	1054,037 42	gr1_vs_all	0,089886 155	0,016874 367	1,01E-07	6,82E-07	0,056813 003	0,122959 308
	Blood_co unt	Eosinophil I percentag e	NA	2318,063 47	gr1_vs_all	- 0,171396 111	0,016817 763	2,44E-24	1,44E-22	- 0,204358 32	- 0,138433 902
	Blood_co unt	Reticulocy te percentag e	NA	2486,760 83	gr1_vs_all	- 0,183624 11	0,016838 487	1,28E-27	9,12E-26	- 0,216626 939	- 0,150621 281
	Blood_co unt	Reticulocy te count	NA	2621,593 7	gr1_vs_all	- 0,191921 891	0,016837 587	5,14E-30	4,67E-28	- 0,224922 955	- 0,158920 826
	Blood_co unt	Mean reticulocyt e volume	NA	2879,219 9	gr1_vs_all	0,190342 318	0,016840 995	1,53E-29	1,18E-27	0,157334 574	0,223350 062
	Blood_co unt	Mean sphered	NA	1382,147 4	gr1_vs_all	0,096530 276	0,016874 651	1,08E-08	8,82E-08	0,063456 569	0,129603 983

	cell volume									
	High light									
Blood co	reticulocyt	NA	1636,954	gr1 vs all	- 0,116035	0,016865	6,14E-12	1,02E-10	- 0,149091	- 0,082980
unt	e percentag		18		625	369			141	109
	e High light				-					-
Blood_co unt	scatter reticulocyt	NA	1794,919 08	gr1_vs_all	0,126640	0,016865 127	6,18E-14	1,40E-12	0,159695	0,093585
	e count				170				219	134
Blood_co	te-to-	NA	2320,668	gr1_vs_all	- 0,167469	0,016829	2,79E-23	1,47E-21	- 0,200454	- 0,134484
uni_lulio	ratio		01		414	000			743	085
Blood_co	to-	NA	4025,766	gr1 vs all	0,252102	0,016795	1,11E-50	1,58E-48	0,219183	0,285021
uni_iailo	te ratio		57		244	7.54			172	310
Blood_co	I-to-	NA	1197,188	ar1 vs all	0,098883	0,016868	4.64E-09	4.03E-08	0,065821	0,131946
unt_ratio	Lymphocy te ratio		49	5	997	862	,	,	634	36
Blood_co	Losinophil I-to-	NA	1753,513	ar1 vs all	- 0 131459	0,016834	6.01E-15	1 62E-13	- 0 164454	- 0 098465
unt_ratio	Lymphocy te ratio		56	g: 1_10_u	782	342	0,01210	1,022 10	487	078
Diago and	Diastolic blood		1566 700		-	0.016920			-	-
ssure	pressure, automate	NA	06	gr1_vs_all	0,167673 583	832	2,47E-23	1,37E-21	0,200659 447	0,134687 719
Body size	d reading Hip									
_measure	circumfere	NA	1485,297 56	gr1_vs_all	0,122304 872	0,016857 01	4,13E-13	8,79E-12	0,089265 738	0,155344 005
Body_size	Body		765 3503		0.060823	0.016862	0.000310	0 000020	0.027773	0.003874
_measure s	index	NA	57	gr1_vs_all	964	83	441	465	425	503
Body_size			1833,736		0,126830	0,016854	5 47E 44	4 005 40	0,093796	0,159865
_measure s	vveight	NA	36	gr1_vs_all	998	639	5,47E-14	1,29E-12	512	484
Sleep	Sleep duration	NA	711,3443 18	gr1_vs_all	0,115188	0,016869 119	8,80E-12	1,40E-10	- 0,148251	- 0,082125
	Past		936 5478		714 0 149693	0.016858			58 0 116652	848 0 182735
Smoking	tobacco smoking	NA	06	gr1_vs_all	771	097	7,19E-19	2,77E-17	508	034
Smoking	Smoking status	Never	858,6913 74	gr1_vs_all	0,127108 87	0,016856 707	4,86E-14	1,23E-12	0,094070 331	0,160147 409
Smoking	Smoking	Previous	647,2117 73	gr1_vs_all	- 0,120313	0,016865	1,01E-12	2,01E-11	- 0,153369	- 0,087256
	Ever		944 9001		346 -	0.016962			761 -	931
Smoking	smoked	NA	72	gr1_vs_all	0,141499 279	366	5,10E-17	1,70E-15	0,174550 87	0,108447 688
Blood_bio	Alanine aminotran	NA	876,6267	ar1 vs all	- 0.089627	0,016881	1.11E-07	7.32E-07	- 0.122715	- 0.056539
cnemistry	sferase		67	0	621	76	·		263	978
Blood_bio chemistry	Apolipopr otein A	NA	1693,685 78	gr1_vs_all	0,141953 307	0,016829 421	3,51E-17	1,21E-15	0,174938 365	0,108968 248
Blood_bio	Aspartate	NA	3101,812	art ve all	- 0.285435	0,016768	1.425-64	2 36E-62	- 0.318300	- 0.252569
chemistry	sferase		43	9' '_*3_ali	133	439	1,722-04	2,002-02	669	597
Blood_bio chemistry	Calcium	NA	924,2341 46	gr1_vs_all	0,105111	0,016869 28	4,72E-10	5,42E-09	0,138174	0,072048
Blood bio	Cholester		996,6518		-	0,016871	4 405 00	4 005 00	-	-
chemistry	ol	NA	92	gr1_vs_all	0,102662 302	716	1,18E-09	1,29E-08	0,135730 258	0,069594 347
Blood_bio chemistry	Creatinine	NA	1874,365 96	gr1_vs_all	0,139589 639	0,016847 108	1,24E-16	4,00E-15	0,106569 915	0,172609 364
Blood_bio	C-reactive	NA	1812,019 63	gr1_vs_all	- 0,138810	0,016859 108	1,91E-16	5,98E-15	- 0,171853	- 0,105767
Blood_bio	Cystatin C	NA	3014,237	art ve all	432 0,145591	0,016843	5 80E 18	2 15E 16	677 0,112577	187 0,178604
chemistry Blood bio	Gamma	IN/A	85	gi i_vs_all	187	833	5,50L-10	2,102-10	-	494
chemistry	glutamyltr ansferase	NA	66	gr1_vs_all	0,106084 28	961	3,31E-10	3,93E-09	0,139158 596	0,073009 964
Blood_bio chemistry	Glucose	NA	727,8082 65	gr1_vs_all	0,105655 085	0,016867 578	3,82E-10	4,45E-09	0,072595 24	0,138714 93
Blood bio	Glycated haemoolo		1535.203		0.112719	0.016861	0.075	0.407.40	0.079670	0.145768
chemistry	bin (HbA1c)	NA	29	gr1_vs_all	874	989	2,37E-11	3,48E-10	983	764
Blood_bio	HDL	NA	1531,475	or1 vs all	- 0.114480	0,016845	1 10E-11	1 70E-10	- 0 147497	- 0.081464
chemistry		10.	66	9•o_an	876	384	.,	.,. 02-10	221	53

	Blood_bio chemistry	IGF-1	NA	2192,813 23	gr1_vs_all	- 0,156108 828	0,016835 747	1,98E-20	8,24E-19	- 0,189106 285	- 0,123111 371
	Blood_bio chemistry	Lipoprotei n A	NA	741,8404 86	gr1_vs_all	- 0,053533 043	0,016883 135	0,001522 22	0,003843 991	- 0,086623 381	- 0,020442 706
	Blood_bio chemistry	Phosphat e	NA	708,5856 9	gr1_vs_all	- 0,081250 948	0,016884 403	1,50E-06	7,55E-06	- 0,114343 769	- 0,048158 126
	Blood_bio chemistry	Total bilirubin	NA	1379,720 03	gr1_vs_all	- 0,085853 638	0,016874 199	3,65E-07	2,15E-06	- 0,118926 459	- 0,052780 816
	Blood_bio chemistry	Testoster one	NA	696,1147 07	gr1_vs_all	- 0,100323 636	0,016874 821	2,80E-09	2,68E-08	- 0,133397 678	- 0,067249 594
	Blood_bio chemistry	Total protein	NA	3626,344 77	gr1_vs_all	- 0,325983 133	0,016733 992	7,82E-84	2,61E-81	- 0,358781 155	- 0,293185 111
	Blood_bio chemistry	Triglycerid es	NA	1495,385 11	gr1_vs_all	- 0,126817 575	0,016856 493	5,54E-14	1,29E-12	- 0,159855 695	- 0,093779 456
	Blood_bio chemistry	Urate	NA	1563,399 11	gr1_vs_all	0,125299 095	0,016859 143	1,11E-13	2,41E-12	0,092255 781	0,158342 408
	Mental he alth	Guilty feelings	NA	692,7864 28	gr1_vs_all	0,137779 094	0,016865 126	3,26E-16	9,58E-15	- 0,170834 134	- 0,104724 054
	Fluid_intel ligence	FI2 : identify largest number	NA	231,9724 23	gr1_vs_all	0,064151 986	0,016878 654	0,000144 621	0,000471 636	0,031070 432	0,097233 54
	Fluid_intel ligence	FI3 : word interpolati on	NA	222,0907 15	gr1_vs_all	0,048566 995	0,016884 286	0,004025 362	0,008985 184	0,015474 402	0,081659 588
	Fluid_intel ligence	Fluid intelligenc e score	NA	848,1665 98	gr1_vs_all	0,134729 79	0,016868 12	1,45E-15	4,01E-14	0,101668 882	0,167790 698
	Fluid_intel ligence	Number of fluid intelligenc e questions attempted within timo limit	NA	790,4942 9	gr1_vs_all	0,175294 397	0,016847	2,68E-25	1,67E-23	0,142274 884	0,208313 91
	Fluid_intel ligence	FI1 : numeric addition test (Online)	NA	196,6802 95	gr1_vs_all	0,055083 648	0,016869 462	0,001095 15	0,002866 885	0,088147 186	- 0,022020 11
	Fluid_intel ligence	identify largest number (Online)	NA	267,5044 29	gr1_vs_all	0,074709 309	0,016866 639	9,49E-06	3,97E-05	0,041651 304	0,107767 314
	Fluid_intel ligence	FI3 : word interpolati on (Online)	NA	364,0994 28	gr1_vs_all	0,093045 703	0,016879 748	3,58E-08	2,50E-07	0,059962 005	0,126129 401
Cognitive Tests	Fluid_intel ligence	FI5 : family relationshi p calculatio n (Online)	NA	206,3365 85	gr1_vs_all	0,052550 872	0,016867 113	0,001838 113	0,004549 784	0,019491 938	0,085609 806
	Fluid_intel ligence	FI7 : synonym (Online)	NA	193,3264 31	gr1_vs_all	- 0,052148 225	0,016891 399	0,002022 51	0,004926 984	- 0,085254 758	- 0,019041 692
	Fluid_intel ligence	FI10 : arithmetic sequence recognitio n (Online)	NA	143,3729 13	gr1_vs_all	- 0,039565 841	0,016867 396	0,018999 981	0,034734 883	- 0,072625 329	- 0,006506 352
	Fluid_intel ligence	FI11 : antonym (Online)	NA	167,3895 08	gr1_vs_all	0,044626 588	0,016883 763	0,008219 119	0,016705 526	0,011535 021	0,077718 154
	Fluid_intel ligence	Fluid intelligenc e score (Online)	NA	816,6245 37	gr1_vs_all	0,156540 736	0,016857 352	1,74E-20	7,56E-19	0,123500 935	0,189580 538
	Pairs_mat ching	Number of correct matches in round	NA	426,2057 86	gr1_vs_all	0,113181 863	0,016845 518	1,88E-11	2,84E-10	0,080165 255	0,146198 472
	Pairs_mat ching	Number of incorrect matches in round	NA	598,1101 95	gr1_vs_all	- 0,108805 048	0,016873 304	1,15E-10	1,48E-09	- 0,141876 116	- 0,075733 979
	Pairs_mat ching	Time to complete	NA	1260,475 39	gr1_vs_all	- 0,191167 865	0,016843 297	8,94E-30	7,45E-28	- 0,224180 110	- 0,158155 61
	Pairs_mat ching	Number of correct	NA	200,6671 52	gr1_vs_all	0,084659 542	0,016872 83	5,27E-07	2,93E-06	0,051589 401	0,117729 682

	in round									
Pairs_mat ching	Time to complete round	NA	185,5293 11	gr1_vs_all	- 0,043388 034	0,016870 043	0,010120 568	0,020040 73	- 0,076452 711	- 0,010323 357
Pairs_mat ching	Pairs matching completio n status	Complete d	193,6296 19	gr1_vs_all	0,054130 279	0,016868 114	0,001333 689	0,003402 267	0,021069 383	0,087191 175
Pairs_mat ching	Pairs matching completio n status	Abandone d	199,7620 88	gr1_vs_all	- 0,056061 333	0,016880 79	0,000898 327	0,002389 168	- 0,089147 074	- 0,022975 592
Prospectiv e_memor y	Time to answer	NA	427,3001 7	gr1_vs_all	- 0,093516 694	0,016867 396	2,99E-08	2,18E-07	- 0,126576 183	- 0,060457 205
Prospectiv e_memor y	Duration screen displayed	NA	675,6311 16	gr1_vs_all	- 0,138482 731	0,016857 423	2,24E-16	6,77E-15	- 0,171522 673	- 0,105442 789
Prospectiv e_memor y	Number of attempts	NA	220,0009 3	gr1_vs_all	- 0,051419 346	0,016865 489	0,002300 291	0,005510 05	- 0,084475 097	- 0,018363 595
Prospectiv e_memor y	Final attempt correct	yes	190,8235 75	gr1_vs_all	0,049148 414	0,016869 742	0,003578 579	0,008059 862	0,016084 327	0,082212 501
Prospectiv e_memor y	Final attempt correct	no	180,6200 97	gr1_vs_all	- 0,046867 6	0,016873 614	0,005481 245	0,011687 091	- 0,079939 276	- 0,013795 924
Prospectiv e_memor y	Prospectiv e memory result	NA	202,5425	gr1_vs_all	- 0,050415 327	0,016864 201	0,002797 449	0,006536 095	- 0,083468 553	- 0,017362 101
Reaction_ time	Number of times snap- button pressed	NA	167,7736 22	gr1_vs_all	0,041849 673	0,016884 191	0,013195 996	0,025328 208	0,008757 266	0,074942 079
Reaction_ time	Duration to first press of snap- button in each round	NA	315,3042 38	gr1_vs_all	0,045910 432	0,016885 069	0,006553 024	0,013567 337	0,079004 559	- 0,012816 304
Reaction_ time	Mean time to correctly identify matches	NA	285,3219 16	gr1_vs_all	- 0,041268 023	0,016879 298	0,014497 196	0,027199 242	- 0,074350 84	- 0,008185 207
Symbol_di git_substit ution	Duration to entering	NA	65,11020 18	gr1_vs_all	- 0,078100 27	0,016878 184	3,73E-06	1,70E-05	- 0,111180 902	- 0,045019 638
Symbol_di git substit ution	Symbol digit completio n status	Complete d	107,3941 39	gr1_vs_all	0,047299 617	0,016882 618	0,005088 105	0,010965 744	0,014210 293	0,080388 941
Symbol_di git_substit ution	Symbol digit completio n status	Abandone d	46,29791 71	gr1_vs_all	- 0,049029 644	0,016889 767	0,003700 571	0,008297 245	- 0,082132 98	- 0,015926 308
Trail_maki ng	Errors before selecting correct item in alphanum eric path (trail #2)	NA	156,6664 22	gr1_vs_all	0,043108 371	0,016874 599	0,010636 519	0,020938 03	0,076181 978	- 0,010034 764
Trail_maki ng	Interval between previous point and current one in numeric path (trail #1)	NA	288,0534 12	gr1_vs_all	0,069221 746	0,016885 147	4,15E-05	0,000148 878	0,102316 026	- 0,036127 466
Trail_maki ng	Interval between previous point and current one in alphanum eric path (trail #2)	NA	731,7566 27	gr1_vs_all	0,153773 405	0,016857 775	7,99E-20	3,19E-18	0,186814 037	0,120732 772
Trail_maki ng	Duration to complete numeric path (trail	NA	291,7605 66	gr1_vs_all	0,070272 747	0,016883 311	3,16E-05	0,000115 851	0,103363 428	- 0,037182 067

	Trail_maki ng	Duration to complete alphanum eric path (trail #2)	NA	740,6914 97	gr1_vs_all	- 0,157328 118	0,016854 272	1,10E-20	5,02E-19	- 0,190361 883	- 0,124294 352
	Trail_maki ng	Trail making completio n status	Complete d	217,2255 1	gr1_vs_all	0,057915 552	0,016880 636	0,000602 683	0,001697 698	0,024830 113	0,091000 99
	Trail_maki ng	Trail making completio n status	Abandone d	386,8988 43	gr1_vs_all	- 0,100623 413	0,016866 774	2,47E-09	2,40E-08	- 0,133681 682	- 0,067565 144
	Trail_maki ng	Total errors traversing numeric path (trail #1)	NA	187,5744 22	gr1_vs_all	0,052127 427	0,016886 656	0,002024 99	0,004926 984	0,085224 664	- 0,019030 19
	Blood_co unt	Haemoglo bin concentrat ion	NA	702,7496 59	gr2_vs_all	- 0,062801 855	0,013529 949	3,48E-06	0,000386 112	- 0,089320 069	- 0,036283 642
	Blood_co unt	Mean corpuscul ar volume	NA	749,6413 05	gr2_vs_all	0,039797 483	0,013539 453	0,003292 101	0,026834 717	- 0,066334 323	- 0,013260 642
	Blood_co unt	corpuscul ar haemoglo	NA	884,2226 48	gr2_vs_all	- 0,047108 75	0,013534 194	0,000501 007	0,008491 636	- 0,073635 283	- 0,020582 216
	Blood_co unt	Platelet count	NA	783,7928 8	gr2_vs_all	0,042049 812	0,013529 146	0,001885 331	0,020562 255	0,015533 172	0,068566 451
	Blood_pre ssure	Pulse rate, automate d reading	NA	680,1579 31	gr2_vs_all	- 0,069281 045	0,013540 131	3,13E-07	7,84E-05	- 0,095819 213	- 0,042742 877
	Body_size _measure s	Hip circumfere nce	NA	675,3063 52	gr2_vs_all	0,055607 212	0,013532 197	3,98E-05	0,001633 12	0,082129 832	- 0,029084 593
	Body_size _measure s	Weight	NA	1012,907 54	gr2_vs_all	- 0,070058 094	0,013528 52	2,26E-07	7,52E-05	- 0,096573 507	- 0,043542 682
	Blood_bio chemistry	Cystatin C	NA	838,8331 57	gr2_vs_all	- 0,040516 615	0,013530 54	0,002752 306	0,024574 16	- 0,067035 986	- 0,013997 244
	Blood_bio chemistry	Glycated haemoglo bin (HbA1c)	NA	688,5316 51	gr2_vs_all	0,050554 348	0,013534 701	0,000188 051	0,004792 804	0,024026 822	0,077081 874
	Blood_bio chemistry	Total bilirubin	NA	796,2584 3	gr2_vs_all	- 0,049547 503	0,013539 065	0,000253 186	0,005725 301	- 0,076083 584	- 0,023011 423
	Fluid_intel ligence	FI1 : numeric addition test	NA	203,7826 34	gr2_vs_all	0,052984 133	0,013534 442	9,08E-05	0,002927 659	0,026457 115	0,079511 152
	Fluid_intel ligence	FI13 : subset inclusion logic	NA	184,7388 36	gr2_vs_all	- 0,049893 521	0,013542 997	0,000230 061	0,005369 735	- 0,076437 306	- 0,023349 736
	Fluid_intel ligence	Number of fluid intelligenc e questions attempted within time limit	NA	177,7164 74	gr2_vs_all	0,039409 143	0,013543 204	0,003619 151	0,028723 417	0,012864 951	0,065953 334
Cognitive Tests	Fluid_intel ligence	FI1 : numeric addition test (Online)	NA	133,6931 6	gr2_vs_all	- 0,037443 034	0,013532 438	0,005663 624	0,038726 51	- 0,063966 124	0,010919 943
	Fluid_intel ligence	identify largest number (Online)	NA	220,9493 91	gr2_vs_all	0,061707 301	0,013528 924	5,11E-06	0,000511 431	0,035191 097	0,088223 505
	Fluid_intel ligence	FI6 : conditiona l arithmetic	NA	141,4684 14	gr2_vs_all	0,037227 362	0,013541 965	0,005981 795	0,039661 277	0,010685 597	0,063769 126
	Numeric_ memory	(Unline) Maximum digits remember ed correctly	NA	263,1420 47	gr2_vs_all	0,058879 892	0,013537 406	1,37E-05	0,000806 423	- 0,085412 72	0,032347 064

Pairs_mat ching	Pairs matching completio n status	Complete d	149,7934 44	gr2_vs_all	- 0,041875 623	0,013530 675	0,001971 415	0,020972 503	0,068395 259	- 0,015355 988
Pairs_mat ching	Pairs matching completio n status	Complete d with pause	164,3188 16	gr2_vs_all	0,045693 634	0,013537 081	0,000738 207	0,010275 584	0,019161 443	0,072225 825
Prospectiv e_memor y	Duration screen displayed	NA	292,4849 7	gr2_vs_all	- 0,059950 047	0,013536 131	9,52E-06	0,000732 012	- 0,086480 377	- 0,033419 718
Prospectiv e_memor y	Number of attempts	NA	223,5066 34	gr2_vs_all	- 0,052238 711	0,013526 68	0,000112 82	0,003318 237	- 0,078750 517	- 0,025726 905
Prospectiv e_memor y	Final attempt correct	yes	142,2597 77	gr2_vs_all	0,036640 349	0,013532 111	0,006781 025	0,042645 239	0,010117 899	0,063162 8
Prospectiv e_memor y	Final attempt correct	no	153,5875 57	gr2_vs_all	- 0,039853 152	0,013534 587	0,003237 618	0,026834 717	- 0,066380 455	- 0,013325 848
Prospectiv e_memor y	Prospectiv e memory result	NA	208,5625 45	gr2_vs_all	- 0,051913 791	0,013525 595	0,000124 281	0,003550 888	- 0,078423 469	- 0,025404 113
Reaction_ time	Duration to first press of snap- button in each round Mean time	NA	302,1921 09	gr2_vs_all	0,044001 217	0,013543 117	0,001159 911	0,014145 258	0,070545 238	0,017457 196
Reaction_ time	to correctly identify matches	NA	323,9180 3	gr2_vs_all	- 0,046850 438	0,013537 642	0,000539 657	0,008784 5	- 0,073383 729	- 0,020317 147
Trail_maki ng	Interval between previous point and current one in numeric path (trail #1)	NA	154,9491 99	gr2_vs_all	0,037235 643	0,013546 883	0,005988 853	0,039661 277	0,063787 047	0,010684 24
Trail_maki ng	Interval between previous point and current one in alphanum eric path (trail #2) Duration	NA	217,5053 93	gr2_vs_all	0,045707 198	0,013543 543	0,000739 842	0,010275 584	0,072252 055	0,019162 341
Trail_maki ng	to complete alphanum eric path (trail #2)	NA	216,3184 7	gr2_vs_all	- 0,045947 574	0,013541 86	0,000692 49	0,010275 584	- 0,072489 132	- 0,019406 017
Blood_co unt	White blood cell (leukocyte) count	NA	3924,093 99	gr3_vs_all	0,271297 87	0,013426 495	5,36E-90	2,68E-87	0,244982 424	0,297613 317
Blood co unt	Red blood cell (erythrocy te) count	NA	798,1869 23	gr3_vs_all	0,058256 475	0,013547 978	1,72E-05	5,98E-05	0,031702 927	0,084810 023
Blood_co unt	Haemoglo bin concentrat ion	NA	2101,442 85	gr3_vs_all	0,187797 331	0,013491 236	7,26E-44	1,21E-41	0,161354 994	0,214239 667
Blood_co unt	Haematoc rit percentag e	NA	1626,736 56	gr3_vs_all	0,153955 62	0,013508 572	5,23E-30	5,03E-28	0,127479 306	0,180431 935
Blood_co unt	Mean corpuscul ar volume	NA	1646,632 3	gr3_vs_all	0,087417 569	0,013541 961	1,10E-10	1,15E-09	0,060875 813	0,113959 325
Blood_co unt	corpuscul ar haemoglo bin	NA	2137,427 29	gr3_vs_all	0,113875 761	0,013529 057	4,08E-17	1,07E-15	0,087359 297	0,140392 225
Blood_co unt	Mean corpuscul ar haemoglo bin concentrat ion	NA	814,1726 58	gr3_vs_all	0,123609 41	0,013521 566	6,65E-20	2,22E-18	0,097107 627	0,150111 192

	Red blood									
Blood_co unt	cell (erythrocy te) distributio	NA	1680,092 06	gr3_vs_all	- 0,093736 64	0,013533 235	4,43E-12	6,24E-11	- 0,120261 293	- 0,067211 988
Blood_co	n width Platelet	NA	1415,021	gr3_vs_all	0,075914	0,013534	2,06E-08	1,27E-07	0,049386	0,102442
Blood_co unt	Platelet	NA	43 1882,215 61	gr3_vs_all	0,116831 154	0,013525 964	6,12E-18	1,80E-16	0,090320 752	0,143341 556
Blood_co unt	Mean platelet (thromboc yte)	NA	911,6544 04	gr3_vs_all	0,032182 103	0,013551 211	0,017564 317	0,032647 429	0,005622 217	0,058741 989
Blood_co unt	Lymphocy te count	NA	3878,599 23	gr3_vs_all	0,273766 113	0,013414 539	9,44E-92	9,44E-89	0,247474 1	0,300058 127
Blood_co unt	Monocyte count	NA	2481,753 64	gr3_vs_all	0,174890 746	0,013504 851	3,20E-38	3,56E-36	0,148421 724	0,201359 769
Blood_co unt	Neutrophil I count	NA	2607,482 53	gr3_vs_all	0,193758 7	0,013492 043	1,46E-46	2,91E-44	0,167314 782	0,220202 618
Blood_co unt	Eosinophil I count	NA	2681,798 86	gr3_vs_all	0,220019 809	0,013466 256	1,15E-59	2,87E-57	0,193626 432	0,246413 186
Blood_co unt	Lymphocy te percentag	NA	788,3391 67	gr3_vs_all	0,063574 886	0,013544 476	2,70E-06	1,08E-05	0,037028 2	0,090121 571
Blood_co unt	Neutrophil I percentag e	NA	914,2681 2	gr3_vs_all	- 0,077966 915	0,013546 415	8,75E-09	5,91E-08	- 0,104517 401	- 0,051416 429
Blood_co unt	Eosinophil I percentag e	NA	1819,823 93	gr3_vs_all	0,134556 603	0,013503 741	2,44E-23	1,11E-21	0,108089 756	0,161023 449
Blood_co unt	Reticulocy te percentag	NA	1993,097 59	gr3_vs_all	0,147171 681	0,013519 147	1,57E-27	1,05E-25	0,120674 64	0,173668 722
Blood_co	Reticulocy	NA	2103,596 17	gr3_vs_all	0,154000 276	0,013518 346	5,53E-30	5,03E-28	0,127504	0,180495 748
Blood_co unt	Mean reticulocyt e volume	NA	1969,984 69	gr3_vs_all	0,130233 697	0,013531 455	6,94E-22	2,89E-20	0,156754 862	0,103712 532
Blood_co unt	High light scatter reticulocyt e percentag e	NA	1526,826 01	gr3_vs_all	0,108229 181	0,013535 667	1,35E-15	2,93E-14	0,081699 761	0,134758 601
Blood_co unt	High light scatter reticulocyt e count	NA	1650,671 82	gr3_vs_all	0,116462 838	0,013535 162	8,16E-18	2,33E-16	0,089934 409	0,142991 268
Blood_co unt_ratio	Lymphocy te-to- Monocyte ratio	NA	1075,566 33	gr3_vs_all	0,077617 476	0,013531 504	9,81E-09	6,54E-08	0,051096 215	0,104138 736
Blood_co unt_ratio	Platelet- to- Lymphocy te ratio	NA	2974,094 36	gr3_vs_all	- 0,186244 257	0,013494 977	3,76E-43	5,37E-41	- 0,212693 925	- 0,159794 588
Blood_co unt_ratio	Neutrophil I-to- Lymphocy te ratio	NA	850,7690 53	gr3_vs_all	- 0,070270 844	0,013545 633	2,15E-07	1,07E-06	- 0,096819 797	- 0,043721 891
Blood_co unt_ratio	Eosinophil I-to- Lymphocy te ratio	NA	1483,005 28	gr3_vs_all	0,111179 951	0,013513 705	2,02E-16	4,92E-15	0,084693 575	0,137666 327
Blood_pre ssure	Pulse rate, automate d reading	NA	968,2091 57	gr3_vs_all	0,098622 01	0,013544 491	3,41E-13	5,33E-12	0,072075 296	0,125168 724
Blood_pre ssure	Diastolic blood pressure, automate d reading	NA	1333,677 08	gr3_vs_all	0,142726 471	0,013508 408	4,94E-26	2,74E-24	0,116250 478	0,169202 463
Smoking	Past tobacco smoking	NA	845,0788 59	gr3_vs_all	- 0,135073 768	0,013528 578	2,00E-23	9,50E-22	- 0,161589 295	0,108558 242
Smoking	Smoking status	Never	937,3074 83	gr3_vs_all	- 0,138746 118	0,013519 256	1,17E-24	6,17E-23	- 0,165243 372	- 0,112248 864
Smoking	Ever smoked	NA	821,9047 75	gr3_vs_all	0,137662 962	0,013529 155	2,88E-24	1,44E-22	0,111146 305	0,164179 619
Blood bio chemistry	Alkaline phosphata se	NA	807,2532 46	gr3_vs_all	0,042726 668	0,013550 862	0,001617 796	0,003974 928	0,016167 467	0,069285 869

	Blood_bio chemistry	Apolipopr otein A	NA	889,5890 18	gr3_vs_all	0,074559 345	0,013523 86	3,56E-08	2,10E-07	0,048053 067	0,101065 623
	Blood_bio chemistry	Aspartate aminotran	NA	1916,776 97	gr3_vs_all	0,176385 743	0,013497 782	6,95E-39	8,69E-37	0,149930 576	0,202840 911
	Blood_bio chemistry	Direct	NA	776,9445 35	gr3_vs_all	0,066755 705	0,013547 572	8,39E-07	3,71E-06	0,040202 951	0,093308 459
	Blood_bio chemistry	Calcium	NA	651,5312 29	gr3_vs_all	0,074097 704	0,013546 402	4,55E-08	2,61E-07	0,047547 245	0,100648 164
	Blood_bio chemistry	Creatinine	NA	1706,150 09	gr3_vs_all	- 0,127062 101	0,013520 104	6,07E-21	2,33E-19	- 0,153561 017	- 0,100563 185
	Blood_bio chemistry	C-reactive protein	NA	886,8460 34	gr3_vs_all	0,067937 168	0,013548 283	5,36E-07	2,44E-06	0,041383 02	0,094491 315
	Blood_bio chemistry	Cystatin C	NA	1102,586 91	gr3_vs_all	- 0,053256 228	0,013540 951	8,42E-05	0,000256 556	- 0,079796 005	- 0,026716 451
	Blood bio chemistry	Gamma glutamyltr ansferase	NA	1163,576 44	gr3_vs_all	0,080408 668	0,013549 591	2,99E-09	2,14E-08	0,053851 957	0,106965 379
	Blood_bio chemistry	Glycated haemoglo bin (HbA1c)	NA	1679,368 29	gr3_vs_all	- 0,123304 961	0,013526 47	8,44E-20	2,72E-18	- 0,149816 354	- 0,096793 568
	Blood_bio chemistry	HDL cholestero	NA	748,2264 76	gr3_vs_all	0,055931 429	0,013533 228	3,60E-05	0,000117 486	0,029406 789	0,082456 069
	Blood_bio chemistry	IGF-1	NA	1294,627 41	gr3_vs_all	0,092165 975	0,013528 583	9,82E-12	1,33E-10	0,065650 44	0,118681 509
	Blood_bio chemistry	Total bilirubin	NA	1687,068 64	gr3_vs_all	0,104978 529	0,013537 493	9,23E-15	1,85E-13	0,078445 53	0,131511 529
	Blood_bio chemistry	Total protein	NA	2526,174 23	gr3_vs_all	0,227085 466	0,013462 874	1,90E-63	6,34E-61	0,200698 719	0,253472 214
	Blood_bio chemistry	Triglycerid es	NA	996,0339 59	gr3_vs_all	0,084469 62	0,013538 743	4,48E-10	3,83E-09	0,057934 171	0,111005 069
	Blood_bio chemistry	Urate	NA	1308,989 56	gr3_vs_all	- 0,104909 364	0,013534 166	9,47E-15	1,86E-13	- 0,131435 842	- 0,078382 886
	Mental_he alth	Guilty feelings	NA	739,9216 18	gr3_vs_all	0,147153 186	0,013525 074	1,68E-27	1,05E-25	0,120644 528	0,173661 845
	Mental_he alth	Risk taking	NA	646,1783 41	gr3_vs_all	0,125697 375	0,013520 764	1,58E-20	5,84E-19	0,099197 165	0,152197 585
	Fluid_intel ligence	Attempted fluid intelligenc e (FI) test.	NA	114,4403 91	gr3_vs_all	0,031061 556	0,013536 226	0,021759 501	0,039490 928	0,004531 041	0,057592 072
	Fluid_intel ligence	numeric addition test	NA	187,4638 8	gr3_vs_all	- 0,048741 205	0,013547 507	0,000321 604	0,000881 107	- 0,075293 831	- 0,022188 579
	Fluid_intel ligence	FI3 : word interpolati on	NA	212,9021 15	gr3_vs_all	- 0,046557 624	0,013554 743	0,000594 085	0,001558 8	- 0,073124 432	- 0,019990 816
	Fluid_intel ligence	FI7 : synonym	NA	143,1515 13	gr3_vs_all	- 0,034979 835	0,013556 452	0,009877 419	0,019598 054	- 0,061549 993	- 0,008409 678
	Fluid_intel ligence	FI8 : chained arithmetic	NA	140,2695 51	gr3_vs_all	0,031534 875	0,013560 739	0,020056 47	0,036800 862	0,004956 315	0,058113 435
	Fluid_intel ligence	FI13 : subset inclusion	NA	128,6956 14	gr3_vs_all	0,034757 593	0,013557 449	0,010361 892	0,020478 048	0,008185 481	0,061329 706
	Fluid_intel	Fluid intelligenc	NA	664,9927 3	gr3_vs_all	0,105632	0,013543 699	6,49E-15	1,35E-13	- 0,132178	- 0,079087
Cognitive Tests		Number of				94				102	110
	Fluid_intel ligence	intelligenc e questions attempted within time limit	NA	687,5869 97	gr3_vs_all	0,152474 407	0,013520 251	2,03E-29	1,69E-27	0,178973 611	0,125975 203
	Fluid_intel ligence	FI1 : numeric addition test (Online)	NA	260,7158 02	gr3_vs_all	0,073017 876	0,013538 399	6,98E-08	3,92E-07	0,046483 102	0,099552 651
	Fluid_intel ligence	identify largest number (Online)	NA	393,7840 44	gr3_vs_all	- 0,109976 997	0,013527 79	4,52E-16	1,05E-14	- 0,136490 978	- 0,083463 016
	Fluid_intel ligence	FI3 : word interpolati on (Online)	NA	313,5159 08	gr3_vs_all	- 0,080119 071	0,013550 788	3,42E-09	2,42E-08	- 0,106678 127	- 0,053560 015
	Fluid_intel ligence	FI4 : positional	NA	119,8403 61	gr3_vs_all	- 0,030992	0,013550 295	0,022190 455	0,040054 974	- 0,057550 991	- 0,004434 809
						5				551	005

	arithmetic (Online)									
Fluid intel ligence	FI5 : family relationshi p calculatio n (Online)	NA	250,7544 82	gr3_vs_all	0,063863 453	0,013538 266	2,40E-06	9,70E-06	0,090397 967	0,037328 938
Fluid_intel ligence	FI6 : conditiona I arithmetic (Online)	NA	223,0633 2	gr3_vs_all	- 0,058699 032	0,013550 981	1,49E-05	5,25E-05	- 0,085258 467	- 0,032139 596
Fluid_intel ligence	FI7 : synonym (Online)	NA	212,3366 99	gr3_vs_all	0,057276 09	0,013559 023	2,41E-05	8,22E-05	0,030700 893	0,083851 286
Fluid_intel ligence	FI13 : subset inclusion logic (Online)	NA	185,2656 92	gr3_vs_all	0,049906 095	0,013551 778	0,000231 382	0,000661 091	0,023345 099	0,076467 09
Fluid_intel ligence	Fluid intelligenc e score (Online) Maximum	NA	651,0302 92	gr3_vs_all	- 0,124797 574	0,013534 531	3,20E-20	1,14E-18	- 0,151324 767	- 0,098270 381
Numeric_ memory	digits remember ed correctly	NA	187,8771 41	gr3_vs_all	0,042038 838	0,013552 538	0,001925 082	0,004649 957	0,015476 352	0,068601 323
Pairs_mat ching	Number of correct matches in round	NA	329,2721 07	gr3_vs_all	- 0,087440 461	0,013525 666	1,04E-10	1,09E-09	- 0,113950 28	- 0,060930 643
Pairs_mat ching	Number of incorrect matches in round	NA	292,9968 05	gr3_vs_all	0,053300 431	0,013554 769	8,44E-05	0,000256 573	0,026733 572	0,079867 291
Pairs_mat ching	Time to complete round	NA	860,5163 39	gr3_vs_all	0,130508 753	0,013533 515	5,78E-22	2,51E-20	0,103983 551	0,157033 956
Pairs_mat ching	Number of correct matches in round	NA	132,5496 38	gr3_vs_all	- 0,055921 417	0,013549 026	3,68E-05	0,000119 19	- 0,082477 021	- 0,029365 814
Pairs_mat ching	Time to complete round	NA	179,4992 21	gr3_vs_all	0,041977 832	0,013543 467	0,001940 917	0,004676 91	0,015433 124	0,068522 54
Pairs_mat ching	Pairs matching completio n status	Complete d with pause	117,6637 09	gr3_vs_all	- 0,032719 822	0,013551 099	0,015762 467	0,029462 556	- 0,059279 488	- 0,006160 157
Prospectiv e_memor y	Time to answer	NA	421,3957 44	gr3_vs_all	0,092224 482	0,013537 566	9,83E-12	1,33E-10	0,065691 34	0,118757 624
Prospectiv e_memor y	Duration screen displayed	NA	728,5252 88	gr3_vs_all	0,149324 341	0,013518 037	2,70E-28	2,07E-26	0,122829 475	0,175819 208
Prospectiv e_memor y	Number of attempts	NA	365,7256 03	gr3_vs_all	0,085478 599	0,013531 582	2,72E-10	2,49E-09	0,058957 186	0,112000 012
Prospectiv e_memor y	Final attempt correct	yes	265,5228 75	gr3_vs_all	- 0,068387 924	0,013539 041	4,43E-07	2,05E-06	- 0,094923 956	- 0,041851 893
Prospectiv e_memor y	Final attempt correct	no	270,2942 69	gr3_vs_all	0,070136 401	0,013541 527	2,25E-07	1,10E-06	0,043595 497	0,096677 305
Prospectiv e memor y	e memory result	NA	339,5006 64	gr3_vs_all	0,084505 904	0,013530 709	4,30E-10	3,71E-09	0,057986 202	0,111025 606
Reaction_ time	Duration to first press of snap- button in each round	NA	505,9865 03	gr3_vs_all	0,073675 06	0,013549 806	5,46E-08	3,12E-07	0,047117 928	0,100232 193
Reaction_ time	to correctly identify matches	NA	508,4257 55	gr3_vs_all	0,073537 028	0,013544 779	5,72E-08	3,25E-07	0,046989 749	0,100084 308
Symbol_di git_substit ution	Duration to entering value	NA	63,04532 63	gr3_vs_all	0,075623 433	0,013547 989	2,41E-08	1,44E-07	0,049069 863	0,102177 004
Trail_maki ng	Errors before selecting correct item in alphanum	NA	179,7302 67	gr3_vs_all	0,049454 624	0,013545 988	0,000261 942	0,000735 792	0,022904 976	0,076004 272

	eric path (trail #2)									
Trail_maki ng	Interval between previous point and current one in numeric path (trail #1)	NA	340,9090 03	gr3_vs_all	0,081923 405	0,013550 595	1,51E-09	1,15E-08	0,055364 726	0,108482 083
Trail_maki ng	Interval between previous point and current one in alphanum eric path (trail #2)	NA	689,5867 91	gr3_vs_all	0,144911 716	0,013525 132	1,01E-26	5,95E-25	0,118402 944	0,171420 488
Trail_maki ng	Duration to complete numeric path (trail #1)	NA	335,5124 04	gr3_vs_all	0,080810 71	0,013549 568	2,50E-09	1,80E-08	0,054254 044	0,107367 376
Trail_maki ng	Duration to complete alphanum eric path (trail #2)	NA	694,1570 41	gr3_vs_all	0,147443 87	0,013522 273	1,29E-27	9,25E-26	0,120940 702	0,173947 037
Trail_maki ng	Total errors traversing alphanum eric path (trail #2)	NA	160,7542 47	gr3_vs_all	0,043470 479	0,013555 037	0,001343 311	0,003325 027	0,016903 094	0,070037 863

Supplementary Table 6. Differences in gene-risk scores approximating endophenotypes for groups of SCZ cases in Dorsolateral prefrontal cortex.

Group-specific gene-risk scores (gene-RS) analysis using clustering of SCZ cases in DLPC from 35 PGC cohorts. Gene-RS are imputed in each cohort using UKBB estimates for SCZ related phenotypes and genes in DLPC tissue. Differences in gene-RS approximating a phenotype are tested via Generalized Linear Model (GLM) with gene-RS the dependent variable and group-specific clustering structure (gr_i versus remaining cases) and covariates the independent variables. Each cohort is tested separately and results are summarized via meta-analysis. The regression coefficient β estimate, standard error, p-value and 95% confidence interval refer to the grouping variable, estimates are corrected for multiple testing in a group-specific manner using Benjamini-Hochberg procedure. The family for GLM applied is always Gaussian due to the continuous nature of gene-RS. Each phenotype-group test is annotated with the corresponding cluster-reliability metric (CRM). The table shows significant and reliable results

(FDR < 0.05 and CRM > 610) for all phenotype classes but cognitive ones and only significant (FDR < 0.05) for cognitive classes.

Supplementary Table 7 (separate file) List of PGC Schizophrenia Working Group members with affiliations

Supplementary Data 1. (separate file)

Prior features construction in tissue-specific models.

H3K27ac ChIP-Seq and ATAC-Seq prior features as well as GWAS derived for CAD and SCZ. The table contains prior features with corresponding GEO access number and data type used to build tissue specific PriLer gene expression models as well as the tissue-model in which they are included. When multiple features share the same PriLer name, the final prior was built as union of gene regulatory regions.

Supplementary Data 2. (separate file)

Significant genes associated with Coronary Artery Disease.

Significant genes after tissue-specific multiple testing correction via Benjamini-Hochberg (FDR ≤ 0.05) associated with CAD across 11 tissues. Gene expression models are built from PriLer in GTEx reference panel and imputed in UKBB and CARDIoGRAM cohorts. UKBB is used as discovery dataset composed of 19,026 cases and 321,916 controls, replication results are derived from meta-analysis of 9 CARDIoGRAM cohorts (13,279 cases and 13,402 controls). Each gene is tested via logistic regression correcting for additional covariates. Z-statistic is defined as the gene estimator divided by its standard error $\frac{\beta}{SEB}$. Each gene is annotated with GWAS from ²⁰ and

from matched GWAS in UKBB (Methods) considering the best result around the TSS gene (200kb window). In both cases, GWASs results are considered significant based on FDR correction. Hence, a gene is considered in a new loci if GWAS best hit in that loci is not significant at 0.05 FDR level, divided per published results²⁰ and matched GWAS respectively.

Supplementary Data 3. (separate file)

Significant pathways associated with Coronary Artery Disease.

Significant pathways after tissue-specific and database-specific multiple testing correction via Benjamini-Hochberg (FDR ≤ 0.05) associated with CAD across 11 tissues. The number of genes detected depends on the intersection between genes in a pathway and reliable genes predicted with PriLer in a certain tissue. Each pathway is tested via logistic regression correcting for additional covariates. Z-statistic is defined as the gene estimator divided by its standard error $\frac{\beta}{SE\beta}$. In addition, each pathway is assigned to one of the possible 3 classes: genes P < pathway P i.e. there is at least one gene in that gene-set more significant than the overall pathway; pathway P < genes P & genes FDR > 0.05 i.e. the pathway is more significant than any gene in that geneset and no genes is significant after multiple testing correction; pathway P < genes P & genes FDR < 0.05 i.e. the pathway is more significant than any gene set and at least one gene pass FDR 0.05 threshold.

Supplementary Data 4. (separate file)

Group-specific Pathways for CAD cases clustering in Liver.

Using the clustering structure of CAD cases from UKBB found in liver, the table reports pathways that are significant (FDR 0.01) in at least one group across all tissues, tested via
Wilcoxon-Mann-Whitney (WMW) for single a group against remaining cases after normalization. The pathways are initially clumped based on gene set definition at jaccard similarity threshold 0.2. Significance is assessed after tissue-specific and group-specific multiple tested correction via Benjamini-Hochberg procedure. The table shows Z-statistic from PALAS for CAD, the genes composing the pathway, the groups with significantly different distribution, and the corresponding WMW estimate and p-value. "Improvement wrt genes" indicates for each group if the p-value of the pathway is lower than the p-value reached by the corresponding genes.

Supplementary Data 5. (separate file)

Significant genes associated with Schizophrenia.

Significant genes after tissue-specific multiple testing correction via Benjamini-Hochberg (FDR ≤ 0.05) associated with SCZ across 10 tissues. Gene expression models are built from PriLer in GTEx and CMC reference panels and imputed in 36 European PGC cohorts and CMC dataset itself. Results from meta-analysis in PGC multiple cohorts are used as discovery for a total of 24,764 cases and 30,655 controls, replication results are derived only for DLPC tissue in CMC from CMC dataset itself (212 controls and 266 cases). Each gene is tested via logistic regression correcting for additional covariates. Z-statistic is defined as the gene estimator divided by its standard error $\frac{\beta}{SE\beta}$. Each gene is annotated with GWAS best result around its TSS (200kb window) and GWAS results are considered significant based on FDR correction. Hence, a gene is considered in a new locus if GWAS best hit in that loci is not significant at 0.05 FDR level.

Supplementary Data 6. (separate file)

Significant pathways associated with Schizophrenia.

Significant pathways after tissue-specific and database-specific multiple testing correction via Benjamini-Hochberg (FDR ≤ 0.05) associated with SCZ across 11 tissues. The number of genes detected depends on the intersection between genes in a pathway and reliable genes predicted with PriLer in a certain tissue. Each pathway is tested via logistic regression correcting for additional covariates. Z-statistic is defined as the gene estimator divided by its standard error $\frac{\beta}{SE\beta}$. Gene-sets databases included are Reactome, Gene Ontology, WikiHuman Pathway and a gene-set for DLPC in CMC panel specifically customized in a previous study⁷.

Supplementary Data 7. (separate file)

Group-specific Pathways for SCZ cases clustering in Dorsolateral prefrontal cortex.

Using the clustering structure of SCZ cases from 35 cohorts of PGC2 found in DLPC, the table reports pathways that are significant (FDR 0.01) in at least one group across all tissues, tested via Wilcoxon-Mann-Whitney (WMW) for single a group against remaining cases after normalization. The pathways in Reactome and GO databases are initially clumped based on gene set definition at jaccard similarity threshold 0.2. The pathways from WikiPathway and CMC Gene Set ⁷ are filtered considering only pathways composed of at least 2 genes. Significance is assessed after tissue-specific and group-specific multiple tested correction via Benjamini-Hochberg procedure, separately for Reactome and GO selection, WikiPathway and CMC Gene Set. The table shows Z-statistic from PALAS for SCZ, the genes composing the pathway, the groups with significantly different distribution, and the corresponding WMW estimate and p-value. "Improvement wrt genes" indicates for each group if the p-value of the pathway is lower than the p-value reached by the corresponding genes.